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ABSTRACT 
The hypothesis tested in this dissertation is that a poxvirus vector system containing influenza 
virus immunogens protects pigs against swine influenza virus (SrV)-associated disease. The 
host range-restricted, highly attenuated, and safety-tested modified vaccinia virus Ankara 
(MVA) strain was used as a vector for influenza virus hemagglutinin (HA) and nucleoprotein 
(NP) genes from the HlNl A/PR/8/34 (PRS) human isolate. This recombinant virus has 
previously been shown to protect mice against lethal challenge with PRE. First, the ability of 
the MVA/PR8 recombinant to protect pigs against SIV was examined. Second, a new 
recombinant, designated NIVA/SrV, was constructed containing the HA and NP genes from a 
field isolate of SIV submitted to the Iowa State University Veterinary Diagnostic Laboratory. 
The MVA/SIV recombinant was evaluated for immunogenicity in vaccinated pigs 
subsequently challenged with SFV. Third, the possibility of inhibition of immune response in 
secondary vaccination, following sequential use of two IvIVA recombinants, was explored 
using the MVA/PR8 and MVA/SIV constructs. The first study demonstrated that protection 
afforded by MVA/PR8 against SFV was less than complete, that infection, clinical signs of 
illness, and viral shedding still occurred, albeit to a lesser degree than in nonvaccinated 
controls. The second study indicated the marked improvement in protection against SIV 
when pigs were vaccinated with the MVA/SIV construct. The third study provided evidence 
that sequential use of such MVA recombinants containing inserts from two strains of 
influenza virus, given two months apart, still generated appropriate immune responses to the 
different inserts. 
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GENERAL INTRODUCTION 
Swine influenza is a major respiratory problem in swine. Infected herds are common 
and widespread. Moreover, there are several antigenically distinct subtypes of the causative 
virus that can produce disease in susceptible pigs. There is only one vaccine available, an 
inactivated product derived from a single strain, which cannot provide protection against all 
virulent strains. Immunity against influenza virus largely consists of a strong subtype-specific 
humoral response to a major surface antigen and a heterotypic cell-mediated response to a 
major internal protein. A live virus vaccine could generate these elements of protection. 
However, the ability of influenza virus to infect numerous species, including humans, and to 
mutate and to undergo genomic reassortment, dampens enthusiasm for introducing live 
strains into a susceptible population. This caution regarding inadequate attenuation suggests 
that use of an innocuous vector to express immunogens of influenza virus in a safe, yet 
effective manner would be beneficial. Numerous candidate vectors have been considered by 
researchers in the past, but one family of viruses in particular has been used extensively, the 
poxviruses. These large, relatively self-sufficient viruses generally induce strong enduring 
immune response in infected individuals. Also, there are members of this family that are not 
pathogenic and thus provide safe alternatives as recombinant vaccine vector candidates. 
The hypothesis to be tested in this dissertation is that a poxvirus vector system 
containing influenza virus immunogens protects pigs against swine influenza virus (SIV)-
associated disease. Three major objectives have been delineated, and each of these has 
several subobjectives. 
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The first objective is to determine whether the HA and NP genes fi^om the human 
influenza virus strain A/PR/8/34 (PR8), when expressed by the modified vaccinia Ankara 
(MVA) strain of vaccinia virus, provide adequate protection in pigs against a heterologous 
SrV challenge. Subobjectives of this objective are to, first, compare the intramuscular (IM) 
route of inoculation with intranasal (IN) administration in protecting vaccinates; second, 
determine whether the MVA strain alone, without insertion of foreign genes, has an effect on 
the immune response of pigs, as compared to pigs receiving no vaccination prior to challenge; 
third, determine whether the MVA strain is replication incompetent in certain cells or cell 
lines of swine, as it has been shown to be in those of other mammals; and, fourth, determine 
whether the MVA recombinant can pass the mouse safety test required for licensure of live 
virus vaccines, as described in the United States' Code of Federal Regulations, Chapter 9, 
part 113.33(a). 
The study design for achieving the goals of the first objective and its subobjectives 
will entail the use of colostrum-deprived caesarean-derived pigs, placed in parental MVA and 
recombinant treatment groups, and vaccinated accordingly at 21 and 35 days of age. At 49 
days of age, all pigs, including nonvaccinated controls, will be oronasally challenged with 
pathogenic A/Sw/IN/1726/88 (IN88) and monitored daily for 7 days, at which time the pigs 
will be euthanized. In addition, two porcine cell lines, PK-15 (porcine kidney) and ST (swine 
testicle), as well as primary swine kidney cells, will be evaluated for their ability to sustain 
MVA replication and protein expression. Lastly, nine groups of eight mice each will each 
receive one of three viruses (MVA parent, MVA recombinant, or the wild type Western 
Reserve (WR) strain of vaccinia containing HA and NP inserts) by one of three routes, i.e. 
•-> J 
intraperitoneally, subcutaneously, or intracranially. A tenth group will serve as negative 
controls. The mice will be monitored for clinical signs for 7 days, then undergo postmortem 
examination. 
The second objective is to determine whether an MVA recombinant containing HA 
and NP genes from a porcine strain of influenza virus, administered either by IM or IN route, 
is able to protect pigs against a homologous SIV challenge. Subobjectives of the second 
objective are to, first, use the MVA parental strain to develop a recombinant containing HA 
and NP from Iowa State University Veterinary Diagnostic Laboratory swine isolate #40776 
(ISU SrV); second, evaluate the recombinant's expression of the SIV proteins through 
immunoplaque assay; and, third, determine whether a cell line such as the Madin-Darby 
Canine BCidney (MDCK) line can support SIV growth, reducing the present reliance on 
embryonated egg culture assays. 
To achieve the second group of subobjectives, several steps will be enacted. RNA 
from the ISU SIV strain will be extracted from allantoic fluid of infected egg culture. The 
HA and NP genes will undergo reverse transcription (RT) and poljmierase chain reaction 
(PCR) amplification using published sequences to select primers. The products will be 
cloned, sequenced, then subcloned into the plasmid vector used to develop the first 
recombinant. The plasmid will then be used to transfect the MVA strain. Briefly, MVA-
infected chick embryo fibroblasts will receive plasmid DNA in the presence of a lipophilic 
reagent, then be passaged several times to amplify recombinants. Subsequent plaques 
reactive to SIV Ab in colorimetric immunoassays will be isolated and plaque-purified. The 
selected recombinant (MVA/SIV) will be expanded, then evaluated by immunoassay for HA 
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and NP expression. 
The third objective is to determine whether there is immune response inhibition of 
secondary vaccination following sequential use of the two MVA recombinants, MVA/PR8 
and MVA/SrV. Subobjectives of this third objective are to compare the effects of IN versus 
IM routes of administration on sequential vaccination, and to determine how rapidly titers 
decline following administration of the first recombinant. In addition, sequence analysis of 
the HA and NP genes fi^om the two strains will be performed to determine degree of 
homology. 
The experimental design for achieving the third objective should determine whether 
antibody titer to the MVA vector generated during initial immunization with the PR8 
recombinant can interfere with subsequent immunization using the SFV recombinant, 
MVA/SIV. Six pigs will receive the PR8 recombinant IM and six IN at 21 and 35 days of 
age. Four sentinel pigs will remain unvaccinated. At approximately day 74 and day 88 
following the first vaccination, each of the 12 vaccinated pigs, as well as the 4 nonvaccinated 
pigs, will receive the SIV recombinant, by the IM route. The expectation is that even closely 
spaced, sequential use of the MVA vector will not result in interference to immune response. 
Should the MVA recombinants prove efiBcacious and safe, it would be most convenient to be 
able to administer them and similar constructs repeatedly. 
To accomplish the third set of subobjectives, pig antisera will be evaluated by HAI 
against ISU SFV and PR8 influenza antigen and by SN (constant virus-varying serum 
method) against SIV and MVA. Blood samples will be collected every 2 weeks until day 140 
of the study, or 8 weeks after the last vaccination given. 
5 
Dissertation Organization 
The dissertation is divided into three papers, corresponding to the three major 
objectives to be achieved, each with individual subobjectives, and written for submission to 
particular journals. Each paper is presented as a separate research project, with its own 
Introduction and sections on Materials and Methods, Results, and Discussion. However, 
there will be one Literature Review for all three papers, plus an accompanying reference 
section, prior to discussion of the individual studies, and one section each on General 
Conclusions and References, after the three studies have been presented. The Table of 
Contents may be consulted for specific page notation. 
Literature Review 
Jennerian vaccines In 1798, an English physician by the name of Edward 
Jenner published his observations on the immunity against smallpox provided by inoculation 
with cowpox virus (Jenner 1798). Prior practice had been to inoculate material from mild 
cases of smallpox, but the consequences of this procedure were not always protective. In too 
many instances this caused the disease one hoped to prevent. Others were aware that 
exposure to cowpox seemed to protect against smallpox, well before Tenner's time. But, 
Tenner's methodical approach and careful experimentation helped calm public fears and justify 
community vaccination programs, using a related but nonpathogenic virus to build immunity 
against a dreaded disease (Cartwright & Biddiss 1972). 
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Since that time, there has been steady progress in searching for and developing such 
vaccines. More recently, where candidate vaccines couldn't be found in nature, vaccines have 
been produced through the use of innovative biotechnology. For example, two inactivated 
and six modified live pseudorabies virus (PRV) vaccines are currently licensed as gene-
deleted vaccines (USDA 1998). Gene-deleted vaccines have an advantage in that deleted 
gene products can be used as serologic markers to distinguish vaccinated from infected 
animals (van Oirschot, et al. 1996). Gene-deleted vaccines may also be of low virulence if 
the deleted gene codes for virulence, e. g., Tk-deleted vaccines of PRV have reduced 
virulence (Kit, et al. 1985; Kit, et al. 1987). Such vaccines have played a very important role 
in the national pseudorabies eradication effort. 
As we approach the twenty-first century, biotechnology is changing the character of 
biologies even further. New procedures make it possible to isolate from the genome of a 
highly virulent virus that portion which can provide protective immunity. Insertion of such 
genetic material into another 'carrier" virus then allows expression of specific protective genes 
safely in a vaccine. There are many such live vectored vaccines currently under development 
and several that have been licensed for use in the United States (U. S.) and Europe. The 
vectors used for the vaccines licensed in the U. S. include fowlpox virus, canarypox virus, 
and vaccinia virus (USDA 1998). Fowlpox virus recombinant vaccines carry genes from 
avian influenza virus (Webster, et al. 1991; Webster, et al. 1996) and Newcastle disease virus 
(Taylor, et al. 1996) for use in poultry. Canarypox virus has been used as a vector for canine 
distemper virus genes for disease protection in dogs (Taylor, et al. 1992). Vaccinia virus 
expressing the rabies glycoprotein (G) gene has been used as an oral vaccine for prevention 
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and control of rabies in wildlife. It has been used successfully to protect foxes in Europe and 
raccoons in the United States against epizootic rabies (Brochier, et aL 1990; Desmettre, et al. 
1990). The vaccine appears to be heat-stable enough to survive distribution by airdrop from 
helicopter. The vaccine is also safe, having been tested in over 30 species, as well as 
eflBcacious, to make the possibility of eradication of sylvatic rabies quite real. 
Advantages of recombinant vaccines Many highly pathogenic viruses, for 
which vaccines would be desirable, are too proficient at producing disease to be administered 
in a live product. For example, few if any whole-rabies virus vaccines are sufBciently 
attenuated to warrant administering them live into a susceptible species. Although there are 
many licensed rabies vaccines, they are all inactivated products, with one exception of the 
recombinant vaccinia virus vaccine for wildlife. In addition, even when a virus strain does not 
itself produce disease, it may have characteristics that, when recombined with another strain 
encountered in the field, result in a far worse disease outbreak. Such is the case with 
influenza viruses, which have a segmented genome capable of reassortment. If an attenuated 
vaccine strain, with certain gene segments that give it the ability to replicate well in a given 
host species, should exchange segments with another virulent strain that does not replicate 
well in that species, the outcome may be a new strain that is both virulent and well-adapted to 
the new host. That was the fear that characterized the 1997 Hong Kong outbreak in humans 
of an avian strain of influenza (Claas, et al. 1998b; Suarez, et aL 1998). Fortunately, 
although the avian strain was able to colonize certain humans, it did not replicate well enough 
in that host to cause an epidemic in what would have been a completely susceptible. 
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immunologically naive population. 
Among the veterinary influenza products, there are eight avian vaccines manufactured 
by one company, one swine vaccine, and five types of equine vaccines produced by six 
different companies (USDA 1998). They are all killed virus products, as are the human 
influenza vaccines used in annual vaccination programs. Human vaccines are changed 
annually to reflect the newly emerging strains and frequently contain 3 distinct hemagglutinin 
antigens from diverse strains to maximize protection against disease (Couch, et al. 1996). 
One problem with inactivated influenza vaccines is that the immunity generated is 
only partial (McMichael, et al. 1983). In the presence of a strong adjuvant, antigens can 
stimulate B-cells and induce a good humoral response. However, there is little cell-mediated 
immunity generated by killed product, and this can mean the difference between disease and 
protection or, at least, a more rapid recovery from disease (Wraith, et al. 1987). Also, the 
immunity provided by killed product can be relatively short-lived (Ben-Yehuda, et al. 1993; 
Couch, et al. 1996). The potential advantages of a recombinant vaccine are that it may 
express protective immunogens against even the most dangerous of viruses in a safe vector, 
provide both humoral and cell-mediated immunity, and extend the duration of that protection 
beyond the time provided by an inactivated product. 
Vaccinia virus Vaccinia virus is a member of the Orthopoxviruses. It has made 
unparalleled contributions to the field of immunology. Although the virus is believed to have 
been initially isolated from cows around 1800 for use as an immunizing agent for smallpox, 
some lots of vaccine were reported to have been prepared from pox lesions in horses, or 
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mixed with smallpox virus (Moss 1991; Taylor 1993). The passage of time has obscured its 
origin and culture history (Baxby 1981), but one significant fact is clear: through its use, a 
horrifying and frequently fatal disease was eradicated. Various strains of vaccinia virus were 
used as Jennerian vaccines to protect humans against smallpox, with the end result of 
successfiilly achieving eradication of the disease in 1979 (Fenner, et al. 1988). 
Vaccinia virus is considered to be a viral vector of choice because of its long history 
of use. Moreover, it has a wide host range, lending it to use in all mammalian species. It is 
environmentally durable, not requiring cold storage to retain viability, a valuable feature for 
usage in remote areas of the world. It is relatively nonpathogenic, with gene sequences that 
are well characterized. There is, in fact, a strain for which the sequence of the entire genome 
has been determined. The Copenhagen strain was found to have a genome of 192 
kilobasepairs, with 198 open reading frames (ORF) of at least 60 amino acids, closely-spaced 
genes, and no introns. Other interesting characteristics and homologies included tandem and 
inverted terminal repeats, hairpin loops, conserved motifs for nucleotide binding sites, leucine 
zippers, and zinc fingers (Goebel, et al. 1990; Traktman 1990). 
Vaccinia vims entry into the cell seems to be through pH-independent fiision with the 
plasma membrane; following penetration, there are at least two discrete stages of uncoating 
(Buller & Palumbo 1991; Moss 1990). The first stage occurs at the time of internalization, 
consisting of the release of the phospholipid and roughly half of the viral protein; this stage 
may correspond to the activation of early transcription. The second stage of uncoating is 
characterized by the viral genome becoming sensitive to DNase I and, some suspect, 
corresponds to the decline of early gene transcription. One significant fact is that the vaccinia 
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\'irion contains everything it needs to begin transcription upon entry into the cell (Duller & 
Palumbo 1991; Moss 1990). 
Vaccinia virus has selectable non-essential genes that facilitate foreign gene insertion 
and, with a relatively large virus of roughly 200 kb, it is estimated that it can express up to 30 
kb of inserted DNA. It is known to be a strong inducer of humoral and cell-mediated 
immunity. Vaccinia virus has been used as an experimental vector in several species and in 
accidental human exposure (Jones, et al. 1986), with considerable documentation of its ability 
to induce immunity to several diseases. The first reports of its use as a vector for the delivery 
of immunogens surfaced in the early 1980's. By 1990, there were numerous reports in the 
literature regarding its successful expression of the influenza virus hemagglutinin (Panicali, et 
al. 1983; Smith, et al. 1986) or nucleoprotein (Smith, et al. 1986), the hepatitis B virus 
surface antigen (Paoletti, et al. 1984), the glycoprotein D fi-om herpes simplex virus (Cremer, 
et al. 1985; Paoletti, et al. 1984), the rabies virus glycoprotein (Blancou, et al. 1986), 
envelope a glycoprotein of bovine leukaemia vims (Ohishi, et al. 1988), and other proteins. 
Several studies demonstrated its immunogenicity in humans (Cooney, et al. 1993; Jones, et 
al. 1986). Insertion of more than one gene was also accomplished, such as one recombinant 
expressing both the influenza virus hemagglutinin and the herpes simplex virus thymidine 
kinase gene (Coupar, et al. 1988), or another expressing the hepatitis B vims surface antigen, 
the herpes simplex vims glycoprotein D, and the influenza vims hemagglutinin (Perkus, et al. 
1985). This raised the possibility of a single vector expressing immunogens fi"om multiple 
pathogens, thereby providing protection against all of them with a single vaccine. 
However, as promising as vaccinia vims seemed to be for certain applications, it had 
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several drawbacks which limited its potential for general use. During the smallpox 
eradication effort, it was known to cause unwelcome side effects. Apart from the localized 
irritation induced by the inoculation, there were more severe complications among 
immunocompromised persons. This group consists of those with AIDS and other immune 
system disorders; those undergoing steroidal or cancer therapy; the elderly, the alcoholic, and 
the debilitated; and pregnant women. It was estimated that one in every million vaccinations 
resulted in death (Duller & Palumbo 1992; Fenner, et al. 1988). For this reason, following 
the end of smallpox vaccination, vaccinia virus was no longer used clinically in the U. S. or 
the rest of the world. Once well-exposed to this virus, following decades of little to no use, 
the general population has now become quite susceptible, as people less than 30 years of age 
have no immunity. Unfortunately, this risk of human exposure greatly curtails the usefulness 
of vaccinia as a vector. 
Attenuated or engineered vaccinia viruses To circumvent the problems 
associated with vaccinia virus, while retaining its advantages, researchers investigated strains 
of vaccinia virus that were attenuated, either by nature or design. Strains that were only able 
to produce small plaques in cell culture (Rodriguez & Esteban 1989), that were thymidine 
kinase negative (BuUer, et al. 1985; Taylor, et al. 1991), or that were temperature-sensitive 
mutants (Drillien & Spehner 1983) were evaluated. Some strains were genetically engineered 
to remove genes associated with virulence (Panicali, et al. 1983; Paoletti, et al. 1984; 
Tartaglia, et al. 1992). From these and other studies, several strains emerged that were quite 
promising. One was the NYVAC strain (Tartaglia, et al. 1992), a modified form of the 
Copenhagen strain of vaccinia virus, which had been genetically engineered so that it no 
longer was able to produce infectious virions. Another strain was the modified vaccinia 
Ankara (MVA) strain which also was replication incompetent. Its attenuation was the result 
of about 570 passages in chick embryo fibroblasts, an unnatural host, and not the result of 
direct engineering. Nonetheless, its genome had been investigated and the areas of deletion 
determined (Meyer, et al. 1991). Although no studies have yet directly compared these two 
host-restricted poxviruses, the most critical difference between the two would appear to be 
that the NYVAC strain has a deficiency in replication at an earlier stage than the MVA strain. 
This would mean less protein production with the NY\''AC strain than with MVA, which 
allows for both early and late gene expression. The implication for immunization would be 
that of less protection following use of the NYVAC vector containing foreign gene inserts. 
Nonetheless, its successful use as a vaccine vector has been reported in the literature, where 
expression of foreign antigens provided protection against pseudorabies virus and Japanese 
encephalitis virus in swine (Brockmeier, et al. 1993; Konishi, et al. 1992). 
Alternate poxvirus vectors In addition to pursuing attenuated or engineered 
strains of vaccinia virus, researchers pondered the benefits of using strains of host-specific 
poxviruses as vectors to deliver genes in unnatural hosts. It seemed reasonable to assume 
that, if a modified vaccinia virus so impaired that it cannot replicate is still able to induce 
immunity, then an intact host-restricted poxvirus should be able to do the same. Several of 
these have proven to be successful, specifically the avian poxviruses, one of which is 
currently being used as a licensed veterinary product. As mentioned above, canarypox virus 
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has been used as a vector for a canine distemper vaccine. Canarypox recombinants have also 
been developed that express the measles virus fusion and hemagglutinin glycoproteins 
(Taylor, etal. 1992), the rabies glycoprotein (Cadoz, etal. 1992), and feline leukemia virus 
env and gag proteins (Tartaglia, et al 1993). 
Another approach has been to use host-restricted poxvirus vectors in their natural 
hosts, as vectors to deliver immunogens for protection against other diseases. Examples of 
this strategy include the licensed fowlpox virus vaccines that serve as vectors for avian 
influenza virus (Webster, et al. 1991; Webster, et al. 1996) and Newcastle disease virus 
(Taylor, et al. 1996) genes. The advantage in using this as a vector for poultry is that poultry 
are also vaccinated against fowlpox virus, so this vaccine construct provides several useful 
purposes. Another such candidate vector is swinepox virus. It has been described in the 
literature as successfully expressing genes of pseudorabies (van der Leek, et al. 1994). One 
concern regarding use of swinepox virus is that it can, on occasion, be pathogenic in its host. 
Also, given that it can and will replicate in its host, the potential exists for uncontrolled 
spread of a swinepox recombinant among domestic and feral swine. 
Host range restriction of the MVA strain of vaccinia virus The N'lVA strain of 
vaccinia virus has been well characterized (Altenburger, et al. 1989; Antoine, et al. 1996; 
Bender, et al. 1996; Carroll & Moss 1997; Carroll, et al. 1997; Hirsch, et al. 1996; Mayr, et 
al. 1975; Mayr, etal. 1978; Meyer, etal. 1991; Scheiflinger, etal. 1996; Sutter & Moss 
1992; Sutter, et al. 1994; Wyatt, et al. 1996). It was originally developed from the vaccinia 
virus Ankara strain as a safe alternative for smallpox vaccination, and has been used without 
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significant side-effects in over 120,000 people, including young children and the elderly, for 
immunization against smallpox. After approximately 570 passages in primary chick embryo 
fibroblasts (CEF), it lost its ability to replicate or at least replicate well in numerous 
manmialian cell lines. It contains six major deletions that prevent virus assembly in 
mammalian cells, however, leaving gene expression, both early and late, relatively 
unimpaired. The exact nature of this host restriction is not really understood. Thus far, four 
orthopoxvirus host-range genes have been identified. These are the CHOhr (Gillard, et al. 
1985), C7L (Oguiura, et al. 1993; Perkus, et al. 1990), KIL (Perkus, et al. 1990), and E3L 
(Beattie, et al. 1996; Chang, et al. 1995) genes. Of these, only the function of the E3L gene, 
which expresses an RNA binding protein (Chang, et al. 1992), is known. Regarding the 
others, the CHOhr gene is required for vaccinia to replicate in Chinese hamster ovary cells; 
the CHOhr, KIL, or C7L gene is required in human MRC-5 and porcine kidney PK-15 cells; 
KIL or CHOhr is required in rabbit kidney RK13 cells; and E3L is required in Vero and 
HeLa cells. Compared to its parental strain, MVA has deletions that consist of about 15% 
(30,000 base pairs) of its former genome, including most of the KIL gene (Altenburger, et al. 
1989; Meyer, et al. 1991). Interestingly, in one study, replacement of the KIL gene in MVA 
removed only the host restriction in RK13 cells (Carroll & Moss 1997). This suggests that 
there are multiple, cumulative genetic defects in MVA replication. If so, as seems likely, the 
probability of spontaneous reversion to a wildtype host range is quite low, which increases 
the safety of MVA as a vaccine vector. 
Most host range mutants do not have as broad a host range restriction as that of 
MVA. One study (Meyer, et al. 1991) described the lack of viral multiplication in many 
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different cell lines, including human cervix (HeLa), lung (MRC 5), colon (HRT 18), and 
larynx (Hep-2); monkey kidney (Vero); rabbit kidney (RK13); equine dermal (E-derm); 
bovine lung (BEL) and kidney (MDBK); canine kidney (MDCK); and mouse (DBT) cell 
lines. There was evidence of some replication, reduced about 100-fold, in only two cell lines 
tested, monkey kidney (MAI 04) and chick fibroblast (LSCC-H-32). In a recent study 
supporting these findings (Carroll & Moss 1997), it was determined that MVA could not 
replicate (< 1-fold increase) in rabbit cornea (SIRC), rabbit skin (RAB-9), rabbit kidney 
(RK13), pig kidney (PK-15), human cervix (HeLa), human kidney (SW 839, 293), rhesus 
monkey kidney (FRhK-4), Chinese hamster ovary (CHO), and Chinese hamster lung (CHL) 
cell lines. A few cell Unes were found to be semi-permissive (1- to 25-fold increase) to MVA 
growth, namely, Afiican green monkey kidney (BS-C-1, CV-1), and canine kidney (MDCK) 
cell lines. Only two cell lines, both fibroblastic in morphology, were permissive (> 25-fold 
increase). These were a quail embryo (QT35) and a Syrian hamster kidney (BHK-21) cell 
line, neither of which achieved the levels of virus replication demonstrated by MVA in CEF 
cells. 
The host restriction of MVA, although demonstrated in many mammalian cell lines 
(Carroll & Moss 1997; Meyer, et al. 1991), has only been explored in one swine cell line. If 
the inability to assemble infectious MVA virions extends to various swine cells, the risk of 
spread to nonvaccinated individuals or the environment is minimal. Such host-restriction, 
coupled with a large double-stranded DNA genome capable of accomodating 25 kb of 
foreign DNA, make MVA an attractive candidate for SIV vaccine. Moreover, MVA has 
been used successfiilly in the past to vector influenza virus structural proteins in mice 
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(Bender, etaL 1996; Sutter, etaL 1994), parainfluenza virus 3 proteins in cotton rats (Wyatt, 
et al. 1996), and simian immunodeficiency virus env-gag-pol in macaques (Hirsch, et al. 
1996). In addition, it was able to protect against and provide therapy for pulmonary 
metastases in mice (Carroll, et al. 1997). 
MVA is also a practical choice for laboratories interested in developing recombinant 
vaccines. Since 1991, it has been recommended that U. S. researchers working with standard 
vaccinia viruses receive smallpox vaccinations every 10 years and that their work be carried 
out in biosafety level 2 containment (Katz & Broome 1991). Prior to 1991, restrictions were 
even more stringent. Underscoring the avirulence of MVA, the National Institutes of Health 
intramural biosafety committee in 1997 removed the vaccination requirement for work with 
MVA and changed its status to biosafety level 1 contairmient (Carroll &. Moss 1997). 
Nomenclature of Orthomvxoviridae Swine influenza virus (SIV) is a member 
of the family Orthomyxoviridae. Influenza viruses are grouped into types A, B, and C on the 
basis of their nucleoprotein and matrix protein similarities (Lamb & Krug 1996; Murphy & 
Webster 1996). Type A contains, by far, the most pathogenic strains and can infect a wide 
variety of mammalian and avian species. In 1980, the World Health Organization revised the 
system of nomenclature, in the face of increasing awareness of antigenic diversity among 
isolated strains, to provide the information on type, host if nonhuman, geographical location, 
strain number, and, for type A viruses, designation of antigenic specificity (subtype) of the 
surface antigens, hemagglutinin (here, H; also abbreviated HA in other contexts) and 
neuraminadase (N) (Schild, et al. 1980; WHO 1980). By convention, the subtypes are given 
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in parentheses after the rest of the information is provided. An example of this v/ould be 
A/Sw/IN/1726/88 (HlNl), denoting a type A swine strain, # 1726 from Indiana, subtype 
HlNl, isolated in 1988. 
Subtypes of influenza Type A viruses Currently, there are 15 H and 9 N 
subtypes, reflecting the ability of these antigens to be modified by environmental or 
immunological selection (Rohm, et al. 1996). The RNA genome undergoes frequent point 
mutations, on occasion resulting in evolutionary advantage, in a process knovm as antigenic 
drift. But, the segmented genome itself can reassort into new combinations of H and N in the 
presence of another subtype. This process is referred to as antigenic shifts and can result in 
the introduction of new subtypes into a susceptible population. Interspecies transmission, 
mixed infections, and gene reassortment are thought to be responsible for the emergence of 
new human pandemic strains (Webster, et al. 1995). 
The current consensus is that aquatic birds are the reservoirs for all subtypes of 
influenza A viruses (Webster 1998). Waterfowl are enterically infected wth virus, which is 
excreted in high quantities into the waterways that the birds frequent. This provides an 
efficient means for spreading virus to other wild and domestic animals. Avian-origin viruses 
are believed to be responsible for outbreaks of influenza in poultry (Horimoto, et al. 1995) 
and various mammals, e.g. whales (Hinshaw, et al. 1986), seals (Geraci, et al. 1982), and 
pigs (Scholtissek, et al. 1983). Once virus is spread to humans, pigs, or horses, the route of 
infection is primarily respiratory. 
Phylogenetic analysis has indicated the strong probability that all mammalian influenza 
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viruses are derived from an avian ancestor. Strains of ail subtypes, from all species and 
geographic regions, have been sequenced and analyzed. From examination of highly 
conserved sequences in the genome, it would appear that there are five lineages: gull, swine, 
human, 'ancient' equine (not seen since over 15 years ago), and recent equine (Webster 
1998). Of these, swine and human strains have apparently evolved from a conmion ancestor. 
There also appear to be sublineages, due to longitudinal migration patterns of waterfowl, 
such that Europe and Asia have strains that can be distinguished from those isolated in North 
and South America. The inability to restrict the movement of a diverse and widespread 
reservoir species requires that efforts against influenza be directed towards prevention and 
control. 
Influenza virus genome The genome consists of eight (types A and B), seven 
(type C and Dhori virus), or sbc (Thogoto virus) molecules of single-stranded, negative-sense, 
linear RNA for a total of 10-13.6 kb (Murphy 1996). Virions are 80-120 nm in diameter, 
pleomorphic, and enveloped, with large peplomers composed of HA and N proteins 
projecting from the surface. The type A and B viruses have, for structural proteins, three 
polymerase proteins (PA PBl, and PB2), a nucleocapsid protein (NP), a hemagglutinin 
(HA), a neuraminidase (N), and a nonglycosylated matrix protein (M or Mi). There are also 
two nonstructural proteins (NSl, NS2) and an ion channel (Mj). The eight segments of 
RNA, ranging from 890 to 2,341 nucleotides, interact with NP to form a ribonucleoprotein 
(RNP) which associates with the transcriptase complex consisting of PBl, PB2, and PA, to 
form the nucleocapsid (Lamb & Krug 1996). 
Swine influenza virus Swine influenza (SI) is a common disease of pigs caused 
by type A influenza viruses, mostly of the HlNl antigenic subtype (Easterday & Hinshaw 
1992). It was first described in 1918, at the time of the great influenza pandemic responsible 
for the death of 20 million people worldwide, but the virus was not isolated until 1930 
(Easterday & Hinshaw 1992; Shope 1931). Presently, it occurs throughout much of the 
world wherever pigs are found. The disease is characterized by pyrexia, anorexia, dyspnea, 
coughing, sneezing, depression, huddling, and pneumonia. In acutely affected herds, it 
exhibits 100% morbidity, although mortality is low. Without depopulation, SI is likely to 
continue in the herd with episodic occurrences of respiratory disease and reproductive 
problems throughout the year, not just seasonally as was once thought (Nakamura, et al. 
1972). It is currently believed that convalescing pigs may serve as carriers, or as a reservoir 
of SIV, between epizootics. 
With an estimated one-third of pigs in the US affected (Chambers, et al. 1991; 
Easterday Hinshaw 1992; Hinshaw, etal. 1978; Pirtle, et al. 1976; Woods 1975), the 
economic impact of SIV on the swine industry is substantial. Even though SFV is not usually 
extremely virulent, pigs can become very lethargic, pyrexic, and anorexic, generally up to 
about 5 days. With other pathogenic agents present in a herd, such as porcine reproductive 
and respiratory syndrome virus (PRRS), dual synergistic infections can incapacitate a herd. 
SIV prophylaxis Presently, there is one killed product, but no live SIV vaccines 
are commercially available. No strain has yet been found to be both efficacious and 
sufficiently attenuated to serve as a safe live virus vaccine in pigs. In addition, there are 
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ongoing public health concerns regarding the transmission of SFV to humans, with the most 
recent fatality reported in 1994 (Wentworth, et al. 1994). A swine population that is 
vaccinated against SIV would protect agricultural workers from exposure to zoonotic SIV 
strains. Thus, for several reasons, evaluation of the safety and efiBcacy of a recombinant SIV 
vaccine is desirable. As the antigenic characteristics of the dominant SIV strains are very 
stable, without the marked drift observed in human strains, SFV would seem an excellent 
candidate for control by vaccination. For other subtypes of SIV and newly emerging 
variants, additional genes may be inserted to broaden the recombinant's range of 
immunogenicity. 
Mode of infection Infection occurs through inhalation of aerosolized virus, 
resulting in attachment of virus to respiratory epithelium through binding of the distal tip of 
the HA surface protein to sialic acid receptors on the susceptible cell. Virus is endocytosed 
into endosomes which fuse with lysosomes. The resulting acidic pH induces a 
conformational change in HA which exposes a hydrophobic region of HA that can then fuse 
with the endolysosome membrane, releasing ribonucleoprotein into the host cell cytoplasm 
(Bullough, et al. 1994; Lamb & BCrug 1996). Detailed analysis of HA has determined that it 
is, in fact, a trimer of identical subunits, each of which has an HAi (328 residues) and an HA, 
(221 residues) linked by a disulphide bond. The precursor HAo must be cleaved into HAj and 
HA, to allow conformational change to the low pH form required for infectivity. If the 
connecting peptide has the sequence R-X-BC/R-R (where R is the basic amino acid arginine, X 
is a nonbasic amino acid, and K is the basic amino acid lysine), cleavage of HA occurs in the 
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trcms Golgi apparatus by the endogenous protease fiirin. Certain strains of HA having 
multiple basic amino acids adjacent to the cleavage site have been associated with high 
pathogenicity in avian strains (Lamb & BCrug 1996; Senne, et al. 1996). 
Clinical pathology of SIV The pathology induced by SFV occurs throughout 
the respiratory tract and consists of acute inflammation, edema, and necrosis (Murphy & 
Webster 1996). More severe complications, in the form of interstitial pneumonia, thickening 
of alveolar walls, hyperemia, thrombosis, hemorrhage, and necrosis, can occur. Lung lesions 
tend to be bilaterally distributed, predominantly in the cranial and middle lobes. In pigs that 
recover, resolution of lesions may take up to a month. 
The internationally recognized method for evaluation of pathogenicity of avian 
influenza virus (AIV) isolates is by experimental inoculation of chickens. An isolate that 
causes the death of at least six of eight (75%) inoculated 6-week-old susceptible chickens is 
considered "highly pathogenic" (HP) (Senne, et al. 1996). Generally, the H5 and H7 isolates 
are not HP, producing mild, localized infections of the respiratory and intestinal tracts. 
However, systemic infection can occur, producing the acute disease that often results in 
death. Presently, there is no correlate nomenclature for SIV because, traditionally, SFV has 
not incited acute, fulminating, systemic disease. Typically, SFV virulence might be better 
measured in terms of percent of pneumonic pigs among those exposed. However, in recent 
years, there have been periodic occurrences of'atypical' SIV outbreaks. This has led to 
speculation that the relatively stable antigenic profile of SIV, at least in the U. S., may be 
changing. 
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Atypical strains of SIV Reports have appeared in the literature since 1992, 
indicating the occurrence of SIV either associated with unusual signs or exhibiting more 
virulence than expected. First, there was a report from Quebec regarding an HlNl 
variant producing proliferative and necrotizing pneumonia in pigs, with some signs very 
similar to those of the PRRS virus (Dea S., et al. 1992). It may be that this was an instance 
of undetected dual infection, but genetic analysis did reveal more point mutations and 
diversity than generally seen in North American SIV isolates (Rekik, et al. 1994). Other 
cases arose, as well, indicating novel strains of SIV. One such isolate from a severely 
affected herd was designated A/Sw/Nebraska/1/92 (Olsen, et al. 1993). It induced persistent, 
high fevers (up to 42°C) but not much respiratory disease. Given the high degree of 
conserved sequences in U. S. classical SIV strains, it was surprising that the most closely 
related reference HlNl strain had only 94% identity at the nucleotide level and 96% at the 
amino acid level to this SIV isolate. Nonetheless, it was closest genetically to classic HINl 
SIV than to avian or human HlNl viruses. In England, an HlNl strain antigenically 
distinguishable from classic SIV and European avian virus-like HlNl viruses caused a 
sudden increase in SIV cases, but still exhibited the usual clinical signs of coughing, sneezing, 
and anorexia (Brown, et al. 1993). However, upon experimental infection, this strain 
produced a more severe interstitial pneumonia and hemorrhagic l^nnph nodes. 
The significance of the genetic diversity represented by these strains is as yet 
undetermined. It may be that there are no 'atypical' SIV strains, merely a greater degree of 
potential antigenic diversity among field strains than previously noticed. 
Interspecies transmission and reassortment among influenza vimses Subtype 
HlNl influenza viruses have been continuously circulating in U. S. pigs for over 60 years. It 
was believed that the great pandemic of "Spanish flu" in 1918/19, the worst in history, killing 
at least 20 million people worldwide, was either caused by a swine virus or by a human strain 
that entered the pig population at that time (Kaplan & Webster 1977). In 1997, RNA from a 
person who died during that pandemic was extracted from formalin-fixed, paraSin-embedded 
tissue and sequenced (Taubenberger, et al. 1997). All sequences determined were very 
similar to those of classic HlNl SFV, suggesting that human and swine strains share a 
common avian ancestor, existing some time before 1918. The first isolation of SIV did not 
occur until 1930, however, and the 'classical' HlNl swine virus recovered 
(A/Swine/Iowa/15/30) is still much like the majority of SFV found circulating in U. S. pigs 
today. By sequence analysis of the NP genes from various species over time, it was recently 
determined that, at the nucleotide level, the classical SFV NP is human virus-like, but at the 
amino acid level is avian virus-like. Some suggested this implied selection pressure on the 
SIV NP, acquired early from humans, to revert to avian sequences perhaps because of a 
concomitant reassortment with an avian virus. Presumably, the presence of other avian-
origin genome segments would preferentially select for a more avian virus-like NP, given 
NP's critical role in replication (Gammelin, et al. 1989). But this does not appear to be the 
case. Sequence analysis of additional gene segments of classical SFV reveal that most of 
them, as with NP, are more closely related to avian strains, suggesting they ail evolved 
simultaneously (Schultz, et al. 1991). Since it is known the human virus NP is under strong 
pressure to change (Gammelin, et al. 1990; Gorman, et al. 1991), current speculation is that 
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around 1920 a human HlNl strain was transferred into U. S. pigs, thereby releasing that 
strong selective pressure, which in turn allowed the (classical SIV) genes to slowly start to 
evolve back to the original, optimal avian sequences from which mammalian influenza strains 
originated. 
This phenomenon of slow antigenic drift should not be confused, however, with the 
appearance of avian virus-like strains in Europe. Northern Europe saw its first isolate of SIV 
in 1978/79, and although an HlNl virus, its HI was similar to the avian HI but distinct from 
both human and swine HI (Hinshaw, etal. 1984; Scholtissek, etal. 1983). Since then, there 
have been instances where an avian virus has been able to cross species and infect the pig 
population, as with SwGer/81, and cases where reassortment between avian and classical SIV 
has occurred, as with SwHK/82 (Schultz, et al. 1991). In addition, there is a human virus-
like H3N2 subtype that has been isolated on occasion in European pigs since 1980, perhaps 
as a result of the 1968 antigenic shift (Kundin 1970; Shortridge, et al. 1977) and an ability of 
the H3N2 to persist in pigs even when not circulating in the human population (Done & 
Brown 1997). It is interesting that a serological survey conducted in 1988-1989 in U. S. pigs 
found evidence of H3 viruses antigenically similar to the then-current human H3 strains, at 
about 1.1% average prevalence (Chambers, etal. 1991). In addition, a serological survey 
during 1976-1977 detected an incidence of 1.4% for H3N2 infections (Hinshaw, et al. 1978). 
Moreover, in that study, isolation from one herd of a virus antigenically similar to a human 
H3N2 strain was reported. However, complete sequencing to determine whether the isolate 
was of human origin was not performed. So, no H3 human strain has been confirmed as 
present in U. S. pigs. Very recently, the National Veterinary Services Laboratories identified 
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an influenza virus subtype H3N2 isolate from a swine breeding herd in eastern North Carolina 
(interlaboratorj' communication). Abortion and typical signs of influenza were reported in 
the herd, with mortality at approximately 10%. Studies are currently underway to determine 
species of origin and other characteristics of the virus. 
So, at the very least, there are three HA subtypes circulating in pigs at present, classic 
SrV HI, avian virus-like HI, and human virus-like H3. They have been found in various 
permutations of SIV gene segments. One, an H3N1 strain, appeared to be a combination of 
the classic SIV and the human virus-like H3N2 found in swine (Done & Brown 1997). 
Another, an H1N2 isolate believed to be from a human HlNl and the swine-adapted H3N2, 
caused clinical disease in pigs (Brown, et al. 1995). Still another represented a reassortment 
between human and avian strains in symptomatic Italian pigs, providing the first proof that 
pigs can act as 'mixing vessels' for human and avian viruses (Castrucci, et al. 1993). The 
critical role that pigs can play in pandemics was underscored with the discovery that children 
in the Netherlands were sick from avian-human influenza virus generated in pigs, transmitted 
pig-to-person, and person-to-person (Claas, et al. 1994). Normally, avian strains do not 
replicate in humans, and human strains do not replicate in birds. This is a flinction of their 
specific sialyloligosaccharide receptors on the surface of epithelial ceils of the upper 
respiratory tract. In a previous study, it was determined that, of 38 avian influenza strains, 31 
were successfully transmitted to swine (Kida, et al. 1994). Every HA subtype (of 14) had at 
least one strain that grew as well as a swine or human virus. Since then, it has been 
determined that pigs, in fact, have both avian- and human-specific viral receptors present in 
their upper respiratory tract and that some avian strains, with continued replication, acquire 
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the ability to recognize human receptors as they become swine-adapted (Ito, et al. 1998). 
Taken together, these data delineate the danger to humans of a pig population 
unprotected against influenza. If an avian virus with a non-human-type HA is introduced into 
pigs, then reassorts with a human strain, a pandemic among complete susceptibles would 
occur. Although direct interspecies spread from bird to human can happen, as was seen with 
the 1997 Hong Kong H5NI cases (Claas, etal. 1998a; Claas, etal. 1998b; Suarez, et al. 
1998; Yuen, etal. 1998), the virus under those circumstances may not readily adapt to its 
new host and relatively few may be affected. The dangers may be greater in the former 
scenario. 
In summary, interspecies transmission is known to occur and the pig can be infected 
by either avian or human strains and can serve as a 'mixing vessel', wherein gene segments 
from different strains can reassert to produce new viruses. Clearly, a safe, live vaccine vector 
with capacity to express multiple genes, that could be given to induce primary immune 
response or to boost immunity, would be helpful. 
Immunitv to influenza viruses There are numerous factors that influence the 
ability to withstand influenza virus infection. One is the extent of antigenic variation, through 
drift or shift (Askonas, et al. 1982; Yetter, et al. 1980). The more novel the antigenic profile, 
the more susceptible a population of individuals will be. In addition, the immune status of the 
host plays a large role in protection against influenza (Yetter, et al. 1980). The very old and 
the very young, with reduced capacity for generating humoral and cell-mediated immunity, 
are especially vulnerable to influenza infection (Ben-Yehuda, et al. 1993). But even those 
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with a robust immune system are subject to variables which affect the magnitude of the 
immune response generated. These include the history of prior exposure and infection, the 
time since last vaccination, and the degree of antigenic similarity between the vaccine and the 
circulating strain of influenza virus (Couch, et al. 1996). 
Other factors that influence variation in severity and outcome of exposure to influenza 
virus are the site of initial infection and heterotypic immunity (Yetter, et al. 1980). It has 
been determined in mice that an infection initiated throughout the respiratory tract can lead 
readily to a fatal viral pneumonia, whereas an infection initiated in the nares will seldom do 
so. Moreover, once exposed and recovered, mice display a decrease in viral shedding, 
reduced pulmonary infection, and enhanced recovery when exposed to heterotypic strains of 
influenza (Liang, et al. 1994; Yetter, etal. 1980). 
This ability to recover more rapidly from virus infection, but not prevent it, has been 
attributed to the action of cross-reactive type-specific cytotoxic T lymphocytes generated by 
NP priming (Wraith, et al. 1987). Immunity to influenza virus requires antibodies to the 
globular region of the HA molecule. When these are present at the site of virus exposure, in 
sufBcient quantity, the virus is neutralized and infection prevented (Andrew & Coupar 1988; 
Couch & Kasel 1983; Smith, et al. 1983). But even if the HA is too different for humoral 
recognition and infection is initiated, other components of the immune system come into play. 
Interestingly, one study (Liang, et al. 1994) found that the mechanisms are partially different 
between the upper and lower respiratory tract. In the nose, both CD4+ and CD8+ T cells 
were almost entirely responsible for a short-lived heterotypic immunity. In the lungs, the 
short-lived effects of CD8+, but not CD4+, T cells enhanced recovery, but only partly. 
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Some other undetermined mechanism was responsible for a more persistent heterotypic 
protection. Depletion of NK cells did not have an effect on protection in either the lung or 
nose. 
All evidence to date indicates an optimal influenza vaccine should induce both 
neutralizing antibodies and cytolytic T cells to eliminate free virus and infected cells. One 
phenomenon that may affect the performance of vaccines in immunization against influenza is 
that of'original antigenic sin', a term first used to describe the antibody response to influenza 
virus. This was first observed in individuals after an initial infection then reinfection, or 
vaccination, with a new strain of virus. The response was found to be that of boosting 
antibody titers specific to the original infecting strain which only weakly cross-reacted to the 
new strain (de St. Groth & Webster 1966; Francis 1953). Recently, the concept of original 
antigenic sin has been extended to C5rtotoxic T Ijnnphocytes (CTL) (Klenerman & 
Zinkemagel 1998). Following infection of mice with an immunodominant strain of 
lymphocytic choriomeningitis virus, the mice had only a slight cross-reactive response when 
challenged with a mutant strain, reacting primarily to the first virus. If the mutant strain was 
given first, this response was not observed. Instead, CTL responses cross-reacted equally 
well to the mutant and immunodominant strains. Although the mechanism is not yet 
understood, reactivation of strong memory CTL overcomes the slower response of CTL 
precursors (McMichael 1998). How closely related, yet disparate, viral strains have to be for 
this phenomenon to occur, at either the humoral or cell-mediated level, has yet to be 
determined. But the occurrence of original antigenic sin speaks to the need for vaccination 
prior to any infection that will strongly prime the immune system. 
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Selection of an SIV vaccine SIV strains in the U. S. have exhibited little 
antigenic variation over time, with one dominant antigenic type responsible for most disease 
outbreaks. This phenomenon has been attributed to the lack of selection pressure provided 
by the relatively short lifespan of swine and the continual presence of a susceptible 
population, i.e. young pigs without antibodies (Easterday & Hinshaw 1992; Luoh, et al. 
1992). It has previously been demonstrated that monoclonal antibodies generated against the 
human A/PR/8/34 (PR/8) strain are cross-reactive with antigenic sites on A/SwAne/Iowa/31 
(IA/31), a classic example of the dominant antigenic type of SIV in pigs (Gerhard, et al. 
1981). It has also been shown that the HA of A/Sw/In/1726/88 (IN/88) has three antigenic 
sites that correspond to the three sites on the HA of PR/8, located in the loop and distal tip of 
the protein (Luoh, et al. 1992). These findings suggest that some degree of cross-reactivity 
will occur between antibodies generated against the PR/8 strain and various swine influenza 
virus isolates. 
Consequently, in the first study of this thesis, the ability of a recombinant iVTVA 
vector containing influenza virus HA and NP genes fi-om the PR/'8 strain (MVA/PR8) to 
provide immunity to SIV will be evaluated. During a three-month sabbatical in 1992 at the 
National Institutes of Health, Bethesda, MD, I participated in the creation of this 
recombinant, cloning the HA and NP genes into intermediate and transfection vectors, then 
preparing plasmid DNA for transfection into MVA (Sutter, et al. 1994). In the second study 
of this thesis, an MVA recombinant expressing SIV HA and NP genes will be constructed, 
then compared to MVA/PR8 for efiBcacy in protecting pigs against SIV challenge. The strain 
providing the genes will be a field strain isolated in 1992 by the Veterinary Diagnostic 
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Laboratory at Iowa State University, Ames, lA. It has been designated A/Sw/IA/40776/92 
(ISU) and is believed to be of the classic HlNl variety, on the basis of the clinical disease it 
produces and the site of its isolation. The HA and NP genes of this strain will be sequenced 
in the course of these studies and compared to those of a standard HlNl SFV to test this 
supposition. 
MVA vectors used The first of the two MVA recombinants used in these 
studies contains the HA and NP genes firom PR8 in opposite orientation and under the 
control of two optimized synthetic early/late promoters, improved over wild type vaccinia 
virus promoters, following base-by-base analysis of performance (Davison & Moss 1989a; 
Davison & Moss 1989b). It has been shown to provide protection to mice against a lethal 
challenge fi"om PR/8 (Sutter, et al. 1994). The second MVA-vectored construct expresses 
the HA and NP genes firom the field strain ISU, also in opposite orientation and using the 
same strong synthetic promoters as the PR8 vector. 
The significance of HA and NP as immunogens The use of the HA and NP 
gene inserts was not serendipitous. Previous studies have demonstrated that IL\ can induce 
virus-neutralizing antibody (Andrew, et al. 1987; Ben-Yehuda, et al. 1993; Smith, et al. 
1983); however, NP induces only non-neutralizing antibody (Wraith, et al. 1987). NP, 
however, is the major target antigen recognized by type-specific cross-reactive cytotoxic T-
lymphocytes (CTL) (Townsend & Skehel 1984; Yewdell, et al. 1985) whereas HA only 
stimulates subtype-specific CTL (Andrew, et al. 1986; Bennink, et al. 1984). It is known that 
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antibody is important for protection against infection (Webster, et al. 1991); CTL response is 
responsible for recovery from infection (Wraith, et al. 1987). Since most of the protective 
humoral response following exposure to influenza virus is generated against the five 
hypervariable antigenic sites of HA, antibodies to this protein provide immunity to influenza 
viruses with a sufficiently similar HA (Andrew, et al. 1987). 
Route of inoculation The optimal route of vaccine delivery for a respiratory 
pathogen, such as influenza virus, has been a matter of some discussion. One study (Small, et 
al. 1985) found that intranasal (IN) administration of a W recombinant expressing HA, in 
mice protected both lung and nose against homologous challenge, but scarification protected 
only lung. Another group (Meitin, et al. 1991) vaccinated mice either intraperitoneally (IP) 
with a killed PR8 vaccine, stimulating high serum IgG, or IN with a W recombinant 
containing HA,, inducing nasal IgA titers. They found that the lungs but not noses in the IP 
group and the noses but not lungs in the IN group were fixlly protected against challenge. By 
reversing protection in mice recovered from infection with influenza virus, using anti-IgA 
antiserum, it has since been shown that IgA is the primary and perhaps the only factor in nasal 
immunity to influenza virus in mice (Renegar & Small Jr. 1991). To maximize both IgA and 
IgG, several studies have tried to stimulate the 'common mucosal immune system' (Yetter, et 
al. 1980) in mice by intragastric or intrajejunal administration of a W or MVA recombinant 
expressing influenza virus genes (Bender, et al. 1996; Meitin, et al. 1994). They, in fact, 
have been successfiil in attaining mucosal IgA, serum IgG, and CTL activity. Consequently, 
the use of orally-administered enteric-coated capsules was considered for these present 
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studies, but then deemed not a viable option for weanling pigs, though they hold great 
promise for human vaccination programs. 
Inhibition of immune response to secondary vaccination The advent of 
recombinant vaccines capable of expressing numerous foreign inserts has raised the question 
of whether frequent use of such constructs to deliver different antigens might be inherently 
nonproductive (Etiinger & Altenburger 1991; Flexner, etal. 1988; Rooney, et al. 1988). 
Would, in fact, preexisting immunity to the virus adversely affect efficacy? It has been 
thought by some that the immune response generated against a vector would limit its 
replication and prevent adequate expression of the inserts. This, in turn, would inhibit the 
induction of protective immunity against the heterologous proteins. In support of this view, 
one study (Chelyapov, et al. 1988) demonstrated the strength of the immune response to W. 
It showed that antibodies were generated against most of the W structural proteins, 
including those proteins located internally within the virus, in both rabbits and humans, that 
these antibodies in humans were preserved over many years, and that insertion of foreign 
genes did not affect this pattern. Additional reports indicated that preexisting immunity to 
W resulted in reduced titers of antibody to the foreign protein (Cooney, et al. 1991; 
Rooney, et al. 1988), decreased protection (Rooney, et al. 1988), and reduced, transient T-
cell response (Cooney, et al. 1991). Another study (Kundig, et al. 1993) demonstrated that 
vaccination with one W recombinant resulted in long term suppression of the humoral 
response in mice to a second W recombinant's gene product. 
On the other hand, there have been reports of boosting antibody titers in animals 
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given the same recombinant virus, or of induction of immunity against a foreign antigen in 
animals vaccinated with W subsequently inoculated with a recombinant W expressing that 
antigen (Etiinger &. Altenburger 1991; Jones, et al. 1986; Perkus, etal. 1985; Rooney, et al. 
1988). Also, antibody titer to one of the heterologous proteins in a multivalent W 
recombinant did not prevent mice from developing immunity (Flexner, et al. 1988). Still, 
questions have persisted about the adequacy of the response in these cases, even if outright 
suppression has not occurred. 
Interference by maternal antibodv Another concern has been that, even if anti-
W antibody has little effect on the antibody response to a foreign gene product, there may 
stiU be interference from pre-existing maternal antibody to the virus from which the protein 
derives. Some have noted that passively administered polyclonal antibody to a foreign 
protein can inhibit B-cell response to a W recombinant vaccine, but not necessarily the 
cytotoxic T-lymphocyte response (Gralletti, et al. 1995; Johnson, et al. 1993). In one study 
(Brockmeier, et al. 1997), it was found that only one of two W recombinants expressing 
different pseudorabies glycoproteins protected equally well, with or without the presence of 
maternal antibody. This finding suggests that an appropriate choice of insert may allow 
induction of immunity in the presence of maternal antibody. 
Proposed inoculation regimens to improve immunitv To avoid interference in 
secondary vaccination and improve the immune response, some have tried using diversified 
prime and boost regimens for vaccinations, as in priming with a VY recombinant, followed by 
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a subunit vaccine containing the expressed protein. Use of a subunit as booster has met with 
mixed results (Cooney, et al. 1993; Montefiorl, et ah 1992). One study found that use of a 
W recombinant, boosted by a recombinant avian pox virus, resulted in improved T-cell 
responses, better than when using either construct alone (Hodge, et al. 1997). Another study 
determined that mice primed with an influenza virus recombinant and boosted with a W 
construct expressing the same antigen developed strong secondary antigen-specific CDS' T 
cell responses, but only if the vaccines were given in just that order. However, these 
regimens are not appropriate for achieving widespread prophylaxis and therapy on a 
commercial scale. From a practical standpoint, the preferred alternative would be to have 
just one vector, capable of being used safely and repeatedly to express numerous inserts. 
Statement of the Problem 
To date, no work has been presented regarding the use of any W recombinant 
expressing influenza virus proteins for the protection of pigs against SIV. Nor has there been 
any interference study on the MVA strain of W which, though replication incompetent, may 
express sufficient protein to inhibit immune response. These issues will be explored in the 
first, second, and third studies of this project. 
It is possible that the HA and NP genes fi"om swine influenza virus, especially those 
fi"om pathogenic isolates, will provide as good or better immunity to this disease than the 
current inactivated vaccine. In addition, the MVA vector may prove to be a valuable delivery 
system for other viral immunogens. Its extensive history of use, detailed characterization, and 
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strong synthetic promoters make it a model candidate for expressing proteins of pathogenic 
agents. Our ability to test this system now against swine influenza helps us to evaluate its 
potential to prevent other diseases and, at the very least, provides additional data useful in 
evaluation of the entire recombinant vector concept. 
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I. EVALUATION OF IMMUNOGENICITY, SAFETY AND HOST RESTRICTION 
OF THE HIGHLY ATTENUATED MVA STRAIN OF 
VACCINIA VIRUS EXPRESSING HUMAN INFLUENZA VIRUS 
HEMAGGLUTININ AND NUCLEOPROTEIN GENES 
A paper to be submitted to Vaccine 
Patricia L. Foley, Steven K. Hanson, Randall L. Levings, and Prem S. Paul 
ABSTRACT 
The highly attenuated modified vaccinia Ankara (MVA) strain of vaccinia virus was used 
as a vector for the delivery of influenza virus hemagglutinin (HA) and nucleoprotein (NP) 
genes from the HlNl human isolate, A/PR/8/34 (PR/8). The level of antigenic relatedness 
and serologic cross-reactivity between the HA and NP genes of PR/8, the MVA recombinant 
(MVA-HA-NP), and various swine and turkey influenza virus isolates was examined. It was 
determined that, serologically, the HlNl swine and turkey isolates are closely related 
compared to the human PR/8 HlNl strain. In addition, twenty pigs, or five groups of four 
pigs each, were challenged intranasally with 10* EID50 of Sw/IN/1726/88 propagated in 
embryonated chicken eggs. Two groups had been previously vaccinated twice with the M\''A 
recombinant, one group intramuscularly and the other intranasally. Another two groups were 
vaccinated similarly with the parental MVA strain. The fifl:h group remained unvaccinated. 
Pigs vaccinated with the MVA recombinant had significantly less duration and lower titer of 
viral shedding, compared to those vaccinated with the parental strain and nonvaccinated 
49 
challenged controls. This protection was presumably due to cell-mediated immune response 
generated against NP, since humoral response to both HA and NP was undetectable up to the 
day of challenge. All pigs had comparable titers to swine influenza virus HA at 7 days post 
challenge, whereas those vaccinated wnth the recombinant virus had significantly greater 
serologic response to NP when compared to the controls. Also, it was determined that 
MVA-HA-NP was avirulent for mice when given by intracranial, intraperitoneal, or 
subcutaneous route of inoculation. The host restriction of MVA strain replication, previously 
reported for numerous mammalian species, was confirmed in vitro through immunostaining 
of porcine cell culture. 
INTRODUCTION 
Swine influenza (SI) is a common disease of pigs caused by type A influenza viruses, 
mostly of the HlNl antigenic subtype It is characterized by pyrexia, anorexia, dyspnea, 
coughing, sneezing, depression, huddling, and pneumonia. In acutely affected herds, it 
exhibits 100% morbidity, although mortality is low. SI is likely to continue on in a herd that 
is not depopulated, causing recurring outbreaks of respiratory disease and reproductive 
problems. With an estimated one-third of pigs in the U. S. infected with SI 
economic impact on the swine industry is considerable. In addition, there are ongoing public 
health concerns regarding the transmission of SI to humans, which can on occasion result in 
death 
In the U. S., SI virus (SIV) strains have exhibited little antigenic variation over time, with 
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one dominant antigenic type responsible for most disease outbreaks. This phenomenon has 
been attributed to the lack of selection pressure provided by the relatively short lifespan of 
swine and the continual presence of a susceptible population, i.e. young pigs without 
antibodies It has previously been demonstrated that monoclonal antibodies generated 
against the human A/PR/8/34 (PR/8) strain are cross-reactive with antigenic sites on 
A/Swine/Iowa/31 (IA/31), a classic example of the dominant antigenic type of SIV in pigs 
It has also been shown that the hemagglutinin (HA) of A/Sw/In/1726/88 (IN/88) has three 
antigenic sites that correspond to the three sites on the HA of PR/8, located in the loop and 
distal tip of the protein These findings suggest that some degree of cross reactivity will 
occur between antibodies generated against the PR/8 strain and various sv^e influenza 
isolates. If so, the immune response induced by a recombinant virus expressing important 
PR/8 immunogens may protect pigs against SFV. In this study, we evaluated the ability of a 
recombinant vaccinia vector containing influenza virus HA and nucleoprotein (NP) genes 
fi-om the PR/8 strain to provide immunity to SW. 
This recombinant vaccinia vector and the modified vaccinia virus Ankara (MVA) strain 
ft-om which it is derived have been well characterized 34.35 ^^s been used 
without significant side-effects in over 120,000 people for immunization against 
smallpox It contains six major deletions that prevent virus assembly in most all 
mammalian cells tested but leave gene expression, both early and late, intact. This host 
restriction, although demonstrated in many mammalian cell lines has only been examined 
in one cell line of swine. In this study, we determined its restriction to extend to at least three 
cell types. Moreover, we evaluated its ability to pass the mouse safety test required for 
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licensure of live virus vaccines, as described in the U. S. Code of Federal Regulations, 
Chapter 9, part 113.33(a)". 
The recombinant MVA vector contains the HA and NP genes from PR/8 in opposite 
orientation and under the control of two optimized synthetic promoters, and has been shown 
to provide protection to mice against a lethal challenge from PR/8 Previous studies have 
demonstrated that HA can induce virus-neutralizing antibody however, NP induces only 
non-neutralizing antibody NP, however, is the major target antigen recognized by type-
specific cross-reactive cytotoxic T-lymphocytes (CTL) whereas HA only stimulates 
subtype-specific CTL It is known that antibody is important for protection against 
infection and that CTL response accounts for recovery from infection^'. Since most of the 
protective humoral response following exposure to influenza virus is generated against the 
five hypervariable antigenic sites of HA, antibodies to this protein provide immunity to 
influenza viruses with a sufflciently similar HA We examined antisera to MVA-HA-NP, 
PR/8, and various isolates of SIV to determine in vitro their ability to react with the HA of 
PR/8, IN/88, and several avian influenza virus (ATV) isolates from turkeys. We found that, 
serologically, the swine and turkey isolates were more closely related. In addition, sera from 
swine vaccinated with MVA-HA-NP then challenged with IN/88 were evaluated through 7 
days postchallenge for their reactivity in a hemagglutination inhibition (HAI) assay, in a 
competitive ELISA (cELIS A) with influenza type A antibody to NP, and in an agar gel 
immunodifiusion (AGED) assay with type A NP and matrix protein antibody. The humoral 
responses to HA and NP were compared. 
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MATERIALS AND METHODS 
Antisera 
One porcine-origin hyperimmune serum generated against a 1960's SIV field isolate, 
provided by the Diagnostic Virology Laboratory (DVL), National Veterinary Services 
Laboratories (NVSL), and another ferret-origin anti-PR/8 hyperimmune serum, provided by 
the Influenza Division, Centers for Disease Control and Prevention (CDC), were compared in 
an HAI assay for their ability to neutralize the respective homologous virus, as well as IA/31, 
a more recent SIV isolate, and several HlNl AIV isolates fi'om turkey farms in Minnesota 
(MN/88), Missouri (MO/87), and South Dakota (SD/86). Serum samples were also 
collected fi-om 1-, 24-, and 40-day old pigs in a conventional swine herd and tested similarly. 
Four caesarean-derived colostrum-deprived (CDCD) pigs were challenged with 1 ml per 
nostril of 10^ mean egg infectious dose (EID5o)/ml IN/88; their HAI titers were evaluated at 7 
days post challenge against the homologous virus and the avian isolates. Two gnotobiotic 
pigs were inoculated IM with 10® fluorescent focal units (FFU) of MVA-HA-NP at 14 days 
of age and again at 37 days. Serum titers at 14, 35, and 51 days of age were evaluated 
against virus isolates PRy8, IN/88, MN/88, MO/87, and SD/86. 
Vinises 
Vaccinia virus strains MVA, MVA-HA-NP, and the nonattenuated, nonrestricted Western 
Reserve (WR) recombinant, WR-HA-NP, were generously provided by B. Moss, Laboratory 
for Viral Diseases (LVD), National Institute of Allergy and Infectious Diseases (NIAID), 
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National Institutes of Health (NIH). MVA and MVA-HA-NP were grown and titrated by 
fluorescent focal assay in chicken embryo fibroblast cells, using Minimum Essential Medium 
(MEM, Gibco BRL) and 5% fetal bovine serum (FBS), and expressed as FFU. WR-HA-NP 
was propagated on HeLa cells and titrated by plaque assay on BS-C-1 cells, with titers 
expressed as plaque-forming units (PFU). The influenza virus PR/8, provided by the 
Influenza Division, CDC, was propagated in the allantoic sac of 10-day-old embryonated 
chicken eggs at 37° C for 72 hours. IA/31 and a 1960's SIV field isolate were acquired fi'om 
the DVL, NVSL, for use in HAI assays. The challenge virus, IN/88, was provided by 
Virginia Hinshaw, University of Wisconsin. The virus was grown in the allantoic cavity of 
10-day-old embryonated chicken eggs at 37°C for 72 hours, and its EID50 and HA unit titers 
were lO^ Vml and 128, respectively. 
Mouse safety tests 
Using nine groups of eight mice each, the MVA recombinant (10^-^ FFU/ml), the MVA 
parental strain (10^-^ FFU/ml), or the WR recombinant (10®-^ PFU/ml) was inoculated into 
mice using either the intracranial (0.03 ml/mouse), intraperitoneal (0.5 ml/mouse), or 
subcutaneous (0.5 ml/mouse) route of inoculation. Six mice served as uninoculated controls. 
Mice were observed for seven days. 
Immunoassay 
Cells were maintained in a humidified, 5% CO, atmosphere at 37° until the development 
of a complete cell monolayer. ST cells (a swine testicular cell line) and PK-15 cells (a 
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porcine kidney cell line) were grown in Eagle's MEM medium supplemented with 1% L-
glutamine, 1% sodium pyruvate, and 5% FBS. SKP cells (swine kidney primary cells) were 
propagated in Eagle's MEM medium supplemented with 1% L-glutamine, 1% sodium 
pyruvate, and 10% FBS. Following viral inoculation at dilutions of 10'~ and 10'^, at least 10^ 
and 10^ respectively of each virus, the cells were maintained in similar media but containing 
only 2.5% FBS. At 24 or 48 hours after virus inoculation, the cells were incubated with an 
anti-PR/8 HA mouse monoclonal antibody (courtesy of B. Moss, LVD, NIAID, NIH) and 
anti-mouse IgG antibodies conjugated to peroxidase, then stained with o-dianisidine. 
Vaccination/challenge 
At 21 days of age, four groups of four caesarean-derived colostrum-deprived (CDCD) 
pigs were vaccinated with 10* FFU of the MVA parent or the MVA recombinant either 
intramuscularly (IM) or intranasally (IN). This was repeated at 35 days of age. At 49 days 
of age, these sixteen pigs and four unvaccinated controls were challenged intranasally, 1 ml 
per nares, with 10®-^ EID50 of strain IN/88 harvested from allantoic fluid of embryonated 
eggs. The eggs had been inoculated at 10 days with virus isolated from infected pigs. Nasal 
swabs were collected at 2, 3, 4, 5, and 7 days post-challenge and titrated in embryonated 
chicken eggs to determine levels of virus shedding. 
Virus isolation and titration 
Nasal swab samples were placed in tubes containing 2 mis Eagle's MEM supplemented 
with 75 U/ml penicillin G potassium, 225 U/ml streptomycin sulfate, 0.1% gentocin, and 
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1.5% amphotericin B. The tubes were frozen, then thawed, vortex-mixed, and centrifuged at 
400xg for 10 minutes. The allantoic sacs of ten-day-old embryonated eggs were inoculated 
with 0.1 ml of the resulting supernatant and incubated at 37° for 72 hr. The harvested 
allantoic fluids were tested for HA activity. Eggs were inoculated in duplicate to determine 
the presence of virus. For titration, four eggs were inoculated v«th each dilution, up to 10"^, 
and the results tabulated using the method of Spearman-Karber 
Serological assays 
HA and HAI tests were performed in 96-well microtiter plates, using 0.5% chicken 
erythrocytes. For the SIV and PR/8 HAI assay, sera were pretreated using 10% kaolin and 
5% washed chicken erythrocytes, then evaluated at 1:10 or greater dilutions against live virus 
antigen. For the ATV HAI assay, virus inactivated with 0.1% beta-propiolactone served as 
antigen; serial dilutions of antisera began at 1:8. For both assays, four HA units of each virus 
were used to determine serum HAI titers. The AGID assay, used to detect circulating 
antibodies to two type A influenza group-specific antigens, NP and matrix protein (M), was 
conducted as described by Beard'^ using A/TY/MN/3689-I551/81 H5N2 virus to produce 
standardized antigen and antiserum. The type A mfluenza cELISA procedure used was 
similar to that described by Katz et al for vesicular stomatitis virus and made use of type A 
NP recombinant baculovirus antigen cloned from A/Arm Arbor/6/60 type A-specific anti-
NP monoclonal antibody H16 peroxidase-labeled conjugate, ABTS substrate, and 
standardized specific reference antisera. 
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Statistical analysis 
Data was evaluated using an analysis of variance and then the Least Significant Difference 
method to compare means. 
RESULTS 
Cross reactivity between influenza vims isolates 
A low level of HAI cross-reaction between PR/8 antisera and SIV and AIV isolates was 
found using hyperimmune sera (Table 1). The PR/8 hyperimmune sera had the highest titers 
to PR/8. The DVL antisera, however, did not have a detectable titer to PR/8, but did cross 
react with the AIV isolates to differing degree. The conventional herd samples demonstrated 
titers to SIV and AIV that, in one instance, cross-reacted with PR/8. 
Sera from CDCD pigs challenged with SIV demonstrated variability of response to AIV 
antigen at 7 days postchallenge (Table 2). The SD/86 and MN/88 isolates elicited stronger 
reaction than MO/87. 
Testing of the gnotobiotic sera (Table 3) showed that vaccination with MVA-HA-NP 
resulted in high HAI titers to PR/8, up to 1:1280, but response to IN/88 was not detectable. 
Mouse safety 
None of the mice inoculated with the MVA recombinant or the MVA parental strain 
intraperitoneaUy, subcutaneously, or intracranially, or the WR recombinant intraperitoneally 
or subcutaneously, were clinically affected. However, the eight mice that received 
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intracranial inoculation of the WR recombinant were clinically affected. In this group, two 
died and six exhibited weakness and rough coats during the 7-day observation period. 
Susceptibility of cells to vaccinia virus replication 
All three cell types tested demonstrated host restriction, in that none had iVTVA-HA-NP-
or MVA-induced lytic cytopathic effect typical of cells fiilly permissive to vaccinia virus 
replication (Figure 1). The ST and PK-15 lines were also somewhat restrictive to the WR-
HA-NP recombinant, in that the expected cell lysis did not occur in these cell lines. 
However, the WR recombinant induced rapid cytopathic effect and cell lysis in the SKP 
primary cells. Single-cell foci of protein expression were evident for both the recombinant 
strains after immunostaining of infected ST and PK-15 cell monolayers. The stain was more 
pronounced after 48 hours of viral growth in ST and PK-15 cells than after 24 hours in SKPs. 
Efficacy of the recombinant vaccine 
Vaccination with the MVA recombinant did not prevent infection but did provide some 
protection against the amount and duration of virus shedding (Table 4). Use of MVA alone, 
given IM or EN, had an apparent protective effect compared to the nonvaccinated challenged 
controls, but the differences were not significant. Clinical signs, following challenge, were 
not pronounced nor sufiBciently different to distinguish between MVA-HA-NP vaccinates and 
other animals, except on Day 2 postchallenge. On day 2 the nonvaccinated controls 
displayed greater signs of mild to moderate dyspnea (3 out of 4), sneezing (2/4), nasal 
discharge (2/4), coughing (1/4), and elevated temperature (1/4) compared to the other four 
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groups after challenge with virulent influenza virus. Postmortem examination revealed that 
all animals except one receiving MVA-HA-NP intranasally had gross and histopathological 
lesions indicative of SIV infection. 
Following each vaccination, MVA-HA-NP induced higher humoral response to the PR/8 
HA, especially for the IM group (Table 5). However, there was no detectable serologic 
response to HA of IN/88 throughout the vaccination period. At 7 days postchallenge, HAI 
titers of the vaccinates to IN/88 were comparable to those of the nonvaccinated challenged 
controls. The MVA-HA-NP vaccinates demonstrated a stronger immune response on 
cELIS A for type A NP antibody, as well as on the AGED for NP and M antibody, when 
compared to other groups. This suggests that the challenge elicited a booster effect to the 
initial vaccinations. 
Statistical analysis 
Use of the recombinant vaccine by both EM and IN routes resulted in significantly fewer 
days of shedding following SIV challenge (p<0.05) when compared to all groups except that 
given the parent MVA strain by IM route (p>0.08) (Table 6). Titers of shed virus dropped 
significantly for the group vaccinated IN with the recombinant starting on day 4 
postchallenge, and on day 5 for the group receiving the recombinant IM (p<0.05) (Tables 7, 
8). With only five animals per treatment group, small but significant differences between 
groups may have been missed. 
Seven days after SIV challenge, animals that had been vaccinated with MVA-HA-NP had 
significantly higher antibody titer to type A NP when compared to the other groups (Table 
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9). In contrast, HAI titers against the IN/88 strain of SIV were similar in vaccinated and 
nonvaccinated pigs. 
DISCUSSION 
The results of this study are consistent with previous reports regarding the role of NP-
generated immune response during infection with influenza virus Expression of influenza 
virus type A-specific NP by the recombinant MVA-HA-NP did not prevent infection but 
assisted in more rapid recovery from infection. Antibody to PR8 HA did not protect against 
the heterologous SIV challenge. Our study also suggests that both the MVA parent and the 
recombinant MVA-HA-NP can be safely administered to pigs and mice at high doses by 
various routes. Even though both parent and recombinant virus are host-restricted in the 
three tj'pes of porcine cells tested, MVA-HA-NP apparently expresses sufficient protein to 
induce a protective effect in the pig, even to heterologous challenge. Presumably, this is due 
to NP's enhancement of cell-mediated immunity, since there was no detectable humoral 
response to HA prior to challenge nor an apparent booster response following challenge, as 
was seen in the AGID and cELISA tests for NP. If NP-specific CTLs did play a part in viral 
clearance, as has been demonstrated previously, the response was not rapid enough to 
prevent initial infection. Replacement of the PR/8 HA and NP genes with those of IN/88 
should result in a superior vaccine, since previous studies indicate that HA stimulates the 
needed initial protection against homologous influenza challenge 
It has been reported that mice vaccinated against influenza with a vaccinia virus-HA 
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recombinant given by systemic routes (IP, scarification) developed serum antibody that 
protected against lung but not nasal infection. In contrast, intranasal immunization provided 
both serum and nasal antibody and protection against infection at both sites This has 
been attributed to the effect of IgA nasal antibody generated by IN inoculation of virus. We 
investigated the difference between IM and IN inoculation and noted a more rapid clearance 
of virus shedding fi^om the nose in pigs given MVA-HA-NP by nasal route. This presumably 
was not due to HA-specific IgA, since antibody to the recombinant's PR/8-origin HA did not 
react with SIV HA at a detectable level on the HAI assay. It is possible that, although not 
detected in vitro, a low level of IgA antibody was present in vivo to offer some local 
protection. 
It is believed that all mammalian influenza viruses are derived from an avian influenza 
virus but that presently aquatic birds and humans maintain two large and distinct 
reservoirs Swine can be infected by strains from either source Moreover, swine 
are believed to be the primary species generating reassortants and serving as a conduit from 
one reservoir to another for the influenza virus. Phylogenetically, the NP genes of PR/8 and 
classical SIV isolates are closely related But, the NP as well as HA genes of influenza 
viruses found recently in European pigs have been of avian origin These 'avianized' SIVs 
are believed to have arisen by reassortment in pigs of genes from avian and human influenza 
virus strains and have themselves, in turn, infected humans and turkeys In one study of 
73 swine isolates from 11 states in the United States (U. S.), collected from 1976 to 1990, 
and II turkey isolates from 8 states, collected from 1980 to 1989, all genes analyzed from 
the strains infecting pigs were characteristic of SIV, suggesting that U. S. pigs are not all that 
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frequently involved in genetic exchange However, 73% of the turkey isolates contained 
genes of swine origin, implying that turkeys in the U. S. can and do serve as frequent 
recipients of gene transfer. Our findings are consistent with this hypothesis. Whereas 
antisera to classic SIV strains reacted well with both SIV and turkey isolates on HAI assay, 
there is no corresponding response to the human strain, PR/8. Conversely, antisera to PR/8 
or its recombinant antigens did not react with the SIV or ATV antigens studied. This raises 
the possibiUty of developing a single vaccine able to protect both pigs and domestic birds 
against certain strains of influenza virus. 
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Table 1. Serologic cross reactivity of antisera against various influenza virus isolates. 
Serum HAl tilers vs. 7 different HINI influenza virus isolatesB 
Immunizing , 
^ animal virus type DVL IA/31 8750 PR/8 MN/88 SD/86 MO/87 
DVL pig hyperimmune 
PR/8 ferret hyperimmune 
unknown 1 day old pig conventional 
unknown 24 day old pigs'' conventional 
S 1280 
10 
40 
13 
S 1280 
10 
40 
13 
S 1280 
20 
40 
10 
neg 
^ 1280 
20 
neg 
1024 
16 
32 
23 
512 
8 
32 
36 
128 
8 
neg 
6 
^HAI titers are expressed as the reciprocal of the last dilution of antisera inhibiting 4 HA units of virus, 
DVL = 1960's SIV isolate, I/W31 = 1931 SIV isolate, 8750 = 1990's SIV isolate; SD/86, MO/87, and MN/88 = 1980's turkey influenza 
virus isolates. 
^These titers, which indicate maternal immunity, are geometric mean titers (GMT) for six 24-day-old conventional pigs. The 
1-day-old pig also had passive immunity to these isolates. 
neg=negative. For PR8 HAI assay, neg<10; for AIV HAl assay, neg<8. 
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Table 2. Reactivity of sera from pigs challenged with Sw/IN/88 against 
various i^Quenza virus isolates as demonstrated by HAI. 
Days post HAI titers against influenza virus isolates* 
Hg No. chaHenge Sw/IN/88 Ty/SD/86 Ty/MO/87 Ty/MN/88 
68 0 neg neg neg neg 
71 0 neg neg neg neg 
74 0 neg neg neg neg 
125 0 neg neg neg neg 
68 7 20 256 8 64 
71 7 20 64 16 32 
74 7 40 256 16 128 
125 7 40 64 16 128 
*Reciprocal of last dilution which inhibits 4 HA units of influenza virus. 
neg = negative. For STV HAI assay, neg <10; for ATV HAI assay, neg <8. 
Lower titers to homologous SIV are due to procedural differences in the 2 
assays. 
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Table 3. Antibody response of pigs to recombinant virus expressing HA and MP at various 
times after vaccination. 
Pig No. Age (days) 
Days post 
vaccinatioii #1 
HAI titers against influenza virus isolates* 
PR/8 IN/88 Ty/MO/87 Ty/MN/88 Ty/SD/86 
6 14 0 neg neg neg neg neg 
7 14 0 neg neg neg neg neg 
6 35 21 80 neg neg neg neg 
7 35 21 160 neg neg neg neg 
6 51 37 640 neg neg neg neg 
7 51 37 1280 neg neg neg neg 
* 
Titers are expressed as the reciprocal of the last dilution which inhibits 4 HA units of influenza 
virus. Two gnotobiotic pigs were vaccinated IM with MVA-HA-NP on 14 and 37 days of age. 
neg = negative. For SIV" HAI assay, neg <10; for ATV HAI assay, neg <8. 
Figure 1 Immunostaining for influenza virus proteins in cell cultures infected with vaccinia 
virus expressing influenza virus proteins. Column A contains ST cells at 48 hours post-
inoculation. Column B contains PK-15 cells 48 hours postinoculation. Column C contains 
swine kidney cells 24 hours postinoculation. Row I, from left to right, consists of 
uninoculated cell controls. In row 2, each of the cultures was inoculated with the MVA 
strain of vaccinia virus. In row 3, the cultures were infected with the MVA/PR8 
recombinant. Lastly, the cultures in row 4 were infected with the nonattenuated Western 
Reserve strain of vaccinia virus containing the PR/8 HA and NP genes. All monolayers were 
stained with anti-influenza virus HA mouse monoclonal antibody and anti-mouse IgG 
antibodies conjugated to peroxidase. Color developed, following staining with o-dianisidine, 
only in the bottom two rows, confirming protein expression. 
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Tabic 4. Shedding of swine influenza virus in vaccinated and nonvaccinated pigs after challenge 
witii virulent virus 
Pig No. 
Vaccine given 
and route Days shed 
Vaccine titer (log lO) oronasal swabs 
Day 5 titer Day 6 titer Day 7 titer 
77 None 7 4.7 1.0 0.5 
79 7 5.5 3.7 0.5 
91 7 3.7 1.0 1.7 
2239 6 2.5 1.7 0.0 
80 MVA,IM 6 4.0 0.5 0.0 
81 7 2.7 1.0 0.5 
82 6 2.5 0.5 0.0 
83 6 42 1.7 0.0 
84 MVA,IN 6 2.7 1.5 0.0 
85 6 3.2 0.7 0.0 
86 6 3.7 0.5 0.0 
87 6 32 0.5 0.0 
78 MVA(R), IM 6 22 1.2 0.0 
88 6 0.7 0.5 0.0 
89 5 0.7 0.0 0.0 
90 5 0.5 0.0 0.0 
93 MVA(R), IN* 4 0.0 0.0 0.0 
94 5 0.5 0.0 0.0 
95 6 2.5 1.2 0.0 
* 
The 4th pig in the MVA(R), IN group died prior to challenge from trauma unrelated to 
vaccine or challenge. 
Table 5. Serological response in vaccinated and nonvaccinated pigs to challenge with virulent influenza virus. 
Pig No. 
Vaccine given 
and route 
HAI titers vs PR/8 * 
14 dpv 14 dpv 7 dpc 
#1 #2 
HAI titers vs IN/88 
7 dpc cELISA result 7 dpc 
vs Type A NPt 
AGID result 7 dpc vs 
Type A NP, M protein ^  
77 None n n n 10 n n 
79 n n n 40 n wl 
91 n n n 20 s wl 
2239 n n n 80 n 1 
80 MVA, IM n n n 40 n n 
81 n n n 80 n 2 
82 n n n 40 s wl 
83 n n n 20 s wl 
84 MVA, IN n n n 10 n n 
85 n n n 80 n n 
86 n n n 20 n wl 
87 n n n 20 + 1 
78 MVA (R), IM 10 160 160 20 s 3 
88 <10 320 320 40 + 2 
89 40 320 320 20 + 3 
90 n 320 <320 10 + 3 
93 MVA (R), IN n 80 80 40 + 4 
94 n 40 40 40 + 3 
95 n 40 40 <10 s 2 
* Tilers are expressed as the reciprocal of the last dilution which inhibits 4 HA units of virus. 
dpv #1, dpv ^ 2 = days post vaccination #1 and #2, dpc = days post challenge; n = negative. 
t For cELlSA, n = negative (0.0); s = suspect (0.5); + = positive (1.0). 
t For AGID, n = negative (0.0); wl = very weak positive (0.5); 1,2 = weak positive (1.0,2.0); 3 = positive (3.0); 4 = strong positive (4.0). 
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Table 6. Virus shedding by vaccinated and nonvaccinated pigs 
after challenge with swine influenza virus. 
Group Route of Mean days 
vaccination virus shedding* 
Controls — 6.75 
MVA IM 6.25 
MVA EST 6.00 
MVA(R) IM 5.50 
MVA(R) IN 5.00 
* There was a significant difference in vims shedding between 
pigs vaccinated with the recombinant and the nonvaccinated 
controls, following challenge with SW/IN/88: 
Recombinant IM vs Control (p <0.05), 
Recombinant IN vs Control (p <0.05), 
Recombinant IM vs Parent IM (p >0.08), 
Recombinant IN vs Parent IN (p <0.05) and 
Recombinant IM vs Recombinant IN (p >0.25). 
MVA (R) = MVA-HA-NP. 
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Table 7. Effect of immunization with recombinant 
vaccinia vector against SIV challenge. 
Route of Virus titers at DPC 
Group vaccination Day 2 Day 3 Day 4 
Control — 3.56 3.56 4.88* 
MVA (R) - IM IM 4.13 2.50 3.56 
MVA (R) - IN IN 4.42 2-83 1.83* 
*There was no significant difference ia virus titers among 
groups until day 4 post challenge, when the animals 
vaccinated intranasally demonstrate a significantly lower titer 
of virus shedding than the controls (p <0.05). 
DPC = days post challenge; 
MVA (R) = MVA-HA-NP. 
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Table 8. Comparison of virus shedding in vaccinated 
and control pigs 5 days after challenge with 
swine influenza virus. 
Group Route of 
vaccination 
Mean EID50* 
of virus shed 
Controls - •- 4.25 
MVA IM 3.38 
MVA EST 3.25 
MVA(R) IM 1.06 
MVA(R) IN 1.00 
*By day 5 post challenge, both groups vaccinated 
with the recombinant had significantly lower 
amounts of virus shed: 
Recombinant IM vs Control (p <0.05)* 
Recombinant IN vs Control (p <0.05)* 
Recombinant IM vs Parent (p <0.05)* 
Recombinant IN vs Parent (p <0.05)* 
Recombinant IM vs Recombinant IN (p >0.50) 
EID50 = Mean egg infectious dose; 
MVA (R) = MVA-HA-NP recombinant. 
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Table 9. Humoral response in pigs to HA and MP after challenge with virulent 
swine influenza virus. 
Group 
HAI GMT 
7 dpc vs IN/88 
Mean cEIJS A OD at 
7 dpc vs type A NP 
Mean AGED values at 
7 dpc vs type A NP, M protein 
Controls 28 0.13 (N to S) 0.50 (VWP) 
MVA-IM 40 0.25 (N to S) 0.75 (VWP to Weak) 
MVA-IN 24 0.25 (N to S) 0.38G^^egtoVWP) 
MVA(R)-IM 20 0.88 (S) 2.75 (Weak to Pos) 
MVA (R)-IN 20 0.83 (S) 3.00 (Pos) 
<10 Gog = 0) 
10 Gog =1) 
20 Gog = 2) 
40 Gog = 3) 
80 Gog = 4) 
Neg = 0.0 
Sus = 0.5 
Pos = 1.0 
Neg = 0.0 
Very Weak Pos = 0.5 
Weak Pos = 1.0 or 2.0 
Pos = 3.0 
Strong Pos = 4.0 
1. HAI No significant group differences (p>0.75) 
2.ELISA 
Recombinant IM vs Control (p <0.05)* 
Recombinant IN vs Control (p <0.05)* 
Recombinant EM vs Parent IM (p <0.05)* 
Recombinant IN vs Parent IN (p <0.05)* 
Recombinant IM vs Recombinant IN (p >0.50) 
3.AGID 
Recombinant IM vs Control (p <0.05)* 
Recombinant IN vs Control (p <0.05)* 
Recombinant IM vs Parent IM (p <0.05)* 
Recombinant IN vs Parent EN (p <0.05)* 
Recombinant IM vs Recombinant IN (p>0.50) 
Using an Analysis of Variance and then the Least Significant Difference method (LSD) to compare means, 
both groups vaccinated with the MVA recombinant had significantly greater antibody titer to NP, but not 
HA, when compared to all other groups. 
GMT = geometric mean titer; dpc = days post challenge. 
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2. RECOMBINANT VACCINIA VIRUS CONTAINING HEMAGGLUTININ AND 
NUCLEOPROTEIN GENES FROM A PORCINE STRAIN OF 
INFLUENZA VIRUS PROTECTS PIGS AGAINST SWINE INFLUENZA VIRUS 
A paper to be submitted to the American Journal of Veterinary Research 
Patricia L. Foley, MA, DVM; Bruce H. Janke, DVM, PhD; 
lone R. Stoll; Steve Hanson; Prem S. Paul, BVSc, PhD 
Structured Abstract 
Objective - To construct and evaluate eflBcacy of an attenuated recombinant vaccinia virus 
expressing hemagglutinin (HA) and nucleoprotein (NP) genes from a field isolate of SAvine 
influenza virus (SIV). 
Animals - 32 caesarean-derived pigs given only SIV antibody-free colostrum post farrowing 
were used for immunization and evaluation of eflBcacy of the recombinant vaccine. 
Procedure - The HA and NP genes of SIV were amplified by reverse transcription 
polymerase chain reaction (RT-PCR) and cloned. These genes were sequenced and 
subcloned into a transfection vector that facilitated insertion of the SIV sequences into the 
genome of the modified vaccinia virus Ankara (MVA) strain of vaccinia virus. Plaques were 
screened for HA and NP protein expression, purified, and expanded. Thirty pigs of mixed 
sex were placed into five groups of six pigs each. An additional two pigs served as 
nonvaccinated, nonchallenged controls. Two groups of six were vaccinated with the 
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MVA/SrV recombinant, one intramuscularly (IM) and the other intranasally (IN), at 20-22 
days of age. Another two groups of six were vaccinated with an MVA recombinant 
containing HA and NP genes from the human strain A/PR/8/34 (PR8), again one IM and the 
other EST, at the same dosage. Those four groups were reinoculated at 34-36 days of age. At 
49-52 days of age, all pigs, including a fifth group of 6 nonvaccinated controls, were 
oronasally challenged with the homologous SIV strain, using a nebulizer. The pigs were 
monitored and nasal swabs collected until day 5 postchallenge, at which time all 32 pigs were 
euthanized and postmortem lesions examined grossly, histologically, and by 
immunohistochemistry for the presence of SIV. 
Results - Sequence analysis determined the close similarity of this HlNl strain with a 
standard 'classic' strain of SFV, as well as its relative distance from the PR8 strain of 
influenza. The MVA/SFV recombinant expressed well its foreign proteins, grew to high titer 
in pure culture, and induced an immune response in vaccinates. Following vaccination and 
challenge, significant differences were seen between vaccinates and controls in terms of 
clinical scores, days and titers of virus shedding, and lung lesions. 
Conclusions - The vaccination/challenge study indicated the ability of the MVA/SFV vaccine, 
especially given IM, to protect pigs against clinical signs, viral shedding, and gross and 
histological lesions tj^jically associated with swine influenza. 
Clinical Relevance - Awareness of the relative ease with which strains of influenza virus can 
reassert have constramed attempts to develop traditional modified live virus vaccines. The 
recombinant MVA/SIV vaccine provides a modified live virus alternative, inducing humoral 
and cell-mediated immune responses, against SIV. That it appears to work well given IM is 
advantageous to its application in the field. 
Introduction 
Many pathogenic viruses, against which vaccines would be desirable, are simply too 
proficient at producing disease to be administered in a live product. In addition, even when a 
virus strain does not itself produce disease, it may have characteristics that, when recombined 
with those of another strain encountered in the field, result in a far worse disease outbreak. 
Such is the case with influenza viruses, which have a segmented genome capable of 
reassortment. If an attenuated vaccine str^n, with certain gene segments that give it the 
ability to replicate well in a given host species, should exchange segments with another 
virulent strain that does not replicate well in that species, the outcome may be a new strain 
that is both virulent and well-adapted to the new host. That was the fear that characterized 
the 1997 Hong Kong outbreak in humans of an avian strain of influenza Fortunately, 
although the avian strain was able to colonize certain humans, it did not replicate well enough 
in that host to cause an epidemic in what would have been a completely susceptible, 
immunologically naive population. 
Among the veterinary influenza products, there are eight avian vaccines manufactured by 
one company, one swine vaccine, and five equine vaccines produced by six different 
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companies They are all killed virus products, as are the human influenza vaccines used in 
annual vaccination programs. Human vaccines are changed annually to reflect the newly 
emerging strains and frequently contain 3 distinct hemagglutinin antigens from diverse strains 
to maximize protection against disease 
One problem with inactivated influenza virus vaccines is that the immunity generated is 
only partial In the presence of a strong adjuvant, antigens can stimulate B-cells and induce 
a good humoral response. However, there is little cell-mediated immunity generated by a 
killed product, and this can mean the difference between disease and protection or, at least, a 
more rapid recovery from disease Also, the immunity provided by a killed product can be 
relatively short-livedThe potential advantages of a recombinant vaccine are that it may 
express protective immunogens against even the most dangerous of viruses in a safe vector, 
provide both humoral and cell-mediated immunity and extend the duration of that protection 
beyond the time provided by a killed product. 
Vaccinia virus, a member of the Orthopoxviruses," is known to be a strong inducer of 
humoral and cell-mediated immunity Vaccinia virus has been used as an experimental 
vector in several species and in accidental human exposure with considerable 
documentation of its ability to induce immunity to several diseases. The first reports of its 
use as a vector for the delivery of immunogens surfaced in the early 1980's. By 1990, there 
were numerous reports in the literature regarding its successful expression of the influenza 
virus hemagglutinin or nucleoprotein the hepatitis B virus surface antigen the 
glycoprotein D from herpes simplex virus " the rabies virus glycoprotein envelope a 
glycoprotein of bovine leukaemia virus and other proteins. Several studies demonstrated 
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its immunogenicity in humans Insertion of more than one gene was also accomplished, 
such as one recombinant expressing both the influenza virus hemagglutinin and the herpes 
simplex virus thymidine kinase gene or another expressing the hepatitis B virus surface 
antigen, the herpes simplex virus glycoprotein D, and the influenza virus hemagglutinin 
This raised the possibility of a single vector expressing immunogens from multiple pathogens, 
thereby providing protection against all of them with a single vaccine. 
However, as promising as vaccinia \'irus seemed to be for certain applications, it had 
several drawbacks which limited its potential for general use. During the smallpox 
eradication effort, it was known to cause unwelcome side effects. Apart from the localized 
irritation induced by the inoculation, there were more severe complications among the 
immunocompromised. It was estimated that one in every million vaccinations resulted in 
death For this reason, following the end of smallpox vaccination, vaccinia virus was no 
longer used clinically in the U. S. or the rest of the world. Once well-exposed to this virus, 
following decades of little to no use, the general population has now become quite 
susceptible, as people less than 30 years of age have no immunity. Unfortunately, this risk of 
human exposure greatly curtails the usefulness of vaccinia as a vector. Even if a vaccine 
were designed for some one species in the veterinary market, because vaccinia has such a 
wide host range, there exists the potential for inadvertent inter-species spread. 
To circumvent the problems associated with vaccinia virus, yet retain its advantages, 
researchers have investigated strains of vaccinia virus that are attenuated, either by nature or 
design. One such strain is the modified vaccinia Ankara (MVA), for which there have been 
numerous studies jj. originally developed from the vaccinia virus Ankara 
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strain as a safe alternative for smallpox vaccination, and has been used without significant 
side-effects in over 120,000 people, including young children and the elderly, for 
immunization against smallpox. After approximately 570 passages in primary chick embryo 
fibroblasts (CEF), it has lost its ability to replicate or at least replicate well in numerous 
mammalian cell lines. It contains six major deletions that prevent virus assembly in most all 
mammalian cells tested but leave gene expression, both early and late, relatively unimpaired. 
The exact nature of this host restriction is not really understood. Thus far, four orthopox 
virus host range genes have been documented. These are the CHOhr C7L KIL 
and E3L genes. Of these, only the fiinction of the E3L gene, which expresses an RNA 
binding protein is known. Compared to its parental strain, MVA has deletions that consist 
of about 15% (30,000 base pairs) of its former genome, including most of the KIL gene 
Interestingly, in one study, replacement of the KIL gene in MVA removed only the host 
restriction in RX13 cells This suggests that there are multiple, cumulative genetic defects 
in MVA replication. If so, as seems likely, the probability of spontaneous reversion to a wild 
type host range is quite low, which increases the safety of MVA as a vaccine vector. 
In this study, the genes for two immunogenic proteins of the swine influenza virus (SIV) 
were inserted into the MVA strain. The construct was then evaluated for protein expression 
and ability to protect pigs against virulent SIV. We report that this recombinant SIV vaccine 
was a safe and efiBcacious deterrent to disease. 
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Materials and Methods 
Construction of the recombinant - Genomic RNA from the ISU SIV isolate was 
purified from infected allantoic fluid using the Purescript RNA isolation kit (Centra), as 
detailed in Figure 1. HA- and NP-specific primers were used in a Titan One-Tube RT-PCR 
reaction (Boehringer Mannheim) to generate first strand cDNA, then amplified to double-
stranded DNA. The RT-PCR products were cloned into the CloneAmp pAMPl System 
vector (GibcoBRL) for sequencing and subcloning into the JS5 plasmid vector. JS5 contains 
the same double promoters in opposite orientation for dual-gene cloning but not the flanking 
MVA sequences as found in plasmid vector G06 (both vectors courtesy of B. Moss, 
Laboratory of Viral Diseases, NLAED, NIH). It also has more convenient restriction sites for 
gene insertion. Following proper insertion of the two SIV genes, the cassette was removed 
from JS5 and inserted into G06. Following PCR screening of transformed colonies, using 
HA- and NP-specific primers, plasmid DNA was cut with various en2ymes to determine 
correct orientation (figures 2a, 2b, 2c). DNA from 4 clones was used in the presence of 
Lipofectamine Plus reagent (Gibco BRL) to transfect MVA-infected cells (figure 3). Cells 
were passed and positive plaques purified at least six times (figure 4), as previously 
described^®. One plaque was selected for expansion and designated MVA/SIV. 
Cells and Viruses - Vaccinia virus strains MVA and MVA/PR8 were generously 
provided by B. Moss, Laboratory for Viral Diseases (LVD), National Institute of Allergy and 
Infectious Diseases (NIAID), National Institutes of Health (NIH). MVA/SIV was recently 
constructed in our laboratory, as described above, from an Iowa field strain of SIV isolated 
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by the Iowa State University Veterinary Diagnostic Laboratory (courtesy of B. Janke). 
MVA, MVA/PR8, and MVA/SIV were grown at 37°C and 5% CO2 in the second passage of 
chicken embryo fibroblast cells, using M199 medium with F-IO nutrient mixture (M199/F-
10), supplemented with 0.15% bactotryptose phosphate broth, 0.09% Na bicarbonate, 1% 
200 mM L-glutamine, 25 U/ml penicillin G potassium, 75 U/ml streptomycin sulfate, 0.1% 
gentocin, and 5% FBS. 
A I960's SrV field isolate, provided by the Diagnostic Virology Laboratory (DVL), 
National Veterinary Services Laboratories (NVSL), and the ISU field isolate were 
propagated in the allantoic cavity of 10-day-old embryonated chicken eggs at 37°C for 72 
hours. The mean egg infectious dose (EID50) and hemagglutination (HA) units of these SIV 
lots were determined. In addition, a 24-hr-old monolayer of swine testicular (ST) cells, 
seeded at 2 x 10^ cells/ml, and grown at 37°C, in 5% CO2, using Minimum Essential Medium 
(MEM) with Earle's salts (Gibco cat. no. 41500-018), supplemented with 0.22% Na 
bicarbonate, 0.5% edamine, 1% 200 mM L-glutamine, 25 U/ml penicillin G potassium, 75 
U/ml streptomycin sulfate, 0.1% gentocin, 1% sodium pyruvate, and 5% FBS, was used for 
SrV replication. At 24 hours after seeding, medium was decanted and the ST monolayer 
inoculated with virus in sufficient medium to cover the monolayer. Following virus 
adsorption for one hour at 37°C, fi^esh medium was added and the cultures incubated at 37°C 
in 5% COi. 
Titration of viruses - For MVA and MVA recombinant virus titrations, 24-hour old 
CEF cells, seeded at 8 x 10^ cells/ml in 60 millimeter (mm) tissue culture plates under 
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conditions cited above, were prepared. Dilutions of virus were made in M199-F10 media 
containing 2% FBS. Growth medium on the 60 mm plates was decanted and 0.2 ml per 
dilution added. Plates were held at 37°C, 5% COj, for one hour, with rocking every 15 mins. 
The inoculum was then aspirated and the plates refed with 4 mis of 2X MEM containing 10% 
FBS, 1% 200 mM L-glutamine, 25 U/ml penicillin G potassium, 75 U/ml streptomycin 
sulfate, and 0.1% gentocin mixed in equal parts with 1.1% melted agar. The mixture was 
allowed to solidify in the plates, which were then incubated at 37°C, 5% CO,, for 2 to 3 days. 
The agar was removed by washing gently with 0.01 M PBS, pH 7.2, and the plates fixed. 
MVA recombinant-inoculated plates were fixed in 1:1 acetonermethanol, reacted with 
primary antibody, then anti-mouse or anti-swine peroxidase-labeled conjugate. The substrate 
used for these assays was metal enhanced DAB (Pierce, Rockford, EL). Recombinant virus 
titers were determined using insert-reactive anti-HlNl SIV polyclonal antisera and anti-PRS 
HA and NP monoclonal antibodies (courtesy of J. Yewdell, NIAID, NTH) as primary 
antibody, and expressed as plaque-forming units (PFU). MVA titers were determined using 
either cytopathic effect (CPE) or immunofluorescent assay (IFA). For the latter procedure, 
plates were fixed in 80% acetone. The primary antibody was a rabbit-origin anti-vaccinia 
virus polyclonal antisera, reacted with an anti-rabbit FITC-conjugate. The titers were 
expressed as fluorescent focal units (FFU). This EFA procedure was also used on the MVA 
recombinant virus-infected cultures, subsequent to the DAB immunoplaque assay, to 
determine the titer of non-expressing plaques. 
For SIV titration on the ST cell line, 96-well plates were inoculated with 50 ul virus 
dilution per well, centrifiiged at room temperature for 2 hours at 400xg, incubated at 37°C in 
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5% COj, then read by CPE or IF A, using anti-HlNl SIV polyclonal antisera, 5-7 days 
postinoculation. 
Immunoassays - Plaque assays to evaluate recombinant protein expression were 
performed in a maimer similar to virus titrations, described above. For plaque purification, 
however, a live immunostaining procedure was employed, i.e. virus-infected plates were not 
fixed. All other steps were the same. 
Vaccination/Challenge - At 20-22 days of age, four groups of six caesarean-derived 
pigs, that were fed colostrum (Colostrix, Struve Labs) negative for SIV antibody, were 
vaccinated with 10® ° PFU of the plaque-purified MVA/PR8 or MVA/SIV recombinant either 
intramuscularly (TM) or intranasally (IN). Immunization was repeated at 34-36 days of age. 
At 49-52 days of age, these twenty-four pigs and six unvaccinated controls were challenged 
oronasally with approximately 2 mis of the homologous ISU field strain (10®-® EIDso/ml). A 
Satum Nebulizer (Dynax), with an attached plastic face mask held over the animals' faces for 
5 minutes, w^as used to deliver virus to the lower airways of the respiratory tract. At 5 days 
postchallenge, the 30 pigs plus 2 nonvaccinated, nonchallenged control pigs were euthanized 
and lung tissue examined. 
Virus isolation and titration - Nasal swabs were collected from all pigs at 2, 3, 4, 
and 5 days post-challenge and titrated in embryonated chicken eggs to determine levels of 
virus shedding. The nasal swab samples were placed in tubes containing 2 mis Eagle's MEM 
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supplemented with 75 U/mi penicillin G potassium, 225 U/ml streptomycin sulfate, 0.1% 
gentocin, and 1.5% amphotericin B. The tubes were frozen, then thawed, vortex-mixed, and 
centrifliged at 400xg for 10 minutes. Ten-day-old embryonated eggs were inoculated in the 
allantoic cavity with 0.1 ml of the resulting supernatant and incubated at 37° for 72 hr. The 
harvested allantoic fluids were tested for HA activity. Eggs were inoculated in duplicate to 
determine the presence of virus. Samples found to be positive for virus were then titrated. 
For titration, four eggs were inoculated with each dilution and the results tabulated using the 
method of Spearman-Karber 
Serological assays - Serum samples were harvested prior to first vaccination, second 
vaccination, challenge, and euthanasia, then analyzed by hemagglutination inhibition (HAI) 
against the two strains of influenza virus, strains PR8 and ISU, and by serum neutralization 
(SN) of MVA and SW, using the constant virus-varying serum method. 
HA and HAI tests were performed in 96-well microtiter plates, using 0.5% chicken 
erythrocytes. For the SIV and PR8 HAI assay, sera were pretreated using 10% kaolin and 
5% washed chicken erythrocytes, then evaluated at 1:10 or greater dilutions against 
standardized live virus antigen. For these assays, four HA units of each virus were used to 
determine serum HAI titers. 
The MVA SN procedure used 96-well plates containing 24-hour-old monolayers of CEF 
cells, inoculated with 50 ul of a 1:1 mixture of virus and 5-fold dilutions of serum, previously 
incubated at 37°C for 1 hour. The inoculum was decanted afl;er 1 hour, replaced with 200 ul 
of M199/F-10 media, supplemented as above but with only 0.5% FES, and read at 5-7 days 
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by CPE. SN titers were determined by the method of Reed-Muench 
The SrV SN procedure is the same as that used for the MVA SN assay, except for the 
use of the ST cell line, a different maintenance medium (MEM and Earle's salts with no 
FBS), and centrifugation, as described above. 
Post mortem examination - Following euthanasia, lungs were examined grossly and 
histologically for lesions. Tissues were fixed in 10% formalin, processed to paraflBn blocks, 
and mounted on poly-L lysine coated glass slides. An immunohistochemical procedure, using 
a monoclonal antibody produced in mice against influenza viral nucleoprotein, was employed 
to determine the presence of viral antigen in lung tissue. 
Statistical analysis - Data was evaluated using an analysis of variance and then the 
Least Significant Difference method to compare means. To determine geometric mean titer 
(GMT), logio of each titer was summated, then averaged and the antilog determined. 
Because negative titers are '0', 1 was added to all numbers, then subtracted later fi-om the 
averaged GMT. 
Results 
Vaccination/Challenge - Different clinical signs were assigned a numerical value (table 
la) and scored (table lb), with the challenged nonvaccinates having far more signs than the 
vaccinates, including marked anorexia (not scored). The MVA/SIV vaccinates especially 
seemed unaffected by the challenge. Upon necropsy, they had very little to no gross or 
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histopathologicai lung lesions, and little to no virus present in the lung as determined by 
immunohistochemistry (table 2). 
To summarize the gross lesions, they were most severe in the challenged, nonvaccinated 
pigs, with total lung involvement of 2-30%, ahnost entirely affecting cranial and middle lung 
lobes. There were lesions of similar extent and distribution in MVA/PR8 IM and IN pigs 
with <10% total lung involvement in 5 of 6 pigs and 15% in 1 of 6 in each group. One pig in 
the MVA/PR8 IM group had almost no lesions; one pig in the MVA/PR8 EST group had 
lesions nearly as extensive as in some non-vaccinates. There were only minimal lesions in the 
tips of the middle lobes in 2 of 6 IVIVA/SIV IN pigs, with no lesions at all in the other 4 of 6 
MVA/SrV IN pigs or in the MVA/SIV IM pigs. 
Regarding the microscopic lesions, those typical of SIV infection were found in the 
challenged nonvaccinates, with active necrosis of bronchiolar epithelium and proliferative 
lesions of repair continuing 5 days after infection, particularly in the smaller bronchioles. 
There were lesions of similar character but much more focal in MVA/PR8 IN pigs. Lesions 
were also more characteristic of the repair stage, with minimal active necrosis in these pigs. 
Lesions were very mild in the MVA/PR8 IM pigs. There were similar mild lesions in 2 
MVA/SIV IN pigs but slightly more severe in one. There were no lesions in the other 3 
MVA/SrV IN pigs, as well as no lesions in the MVA/SIV IM pigs, with one small exception 
(2 small foci in a cranial lobe). In general, although gross lesions in MVA/PR8 IM and IN 
pigs appeared similar, microscopically, damage in the IM-vaccinated pigs was less severe. 
Likewise, microscopic lesions were almost non-existent in MVA/SIV IM pigs but were 
focally present, though mild, in some MVA/SIV IN pigs. 
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Analysis by immunohistochemistry detected most infected cells in the challenged 
nonvaccinates, which correlates with the presence of active ongoing necrosis of epithelium in 
these pigs. Virus was also still present in the alveoli in these pigs. There was a dramatic 
reduction in virus in ail vaccinated pigs. Although there were more lesions induced in pigs 
vaccinated with MVA/PR8 than in pigs vaccinated with MVA/SIV by the corresponding 
route, virus is apparently cleared more rapidly in vaccinated pigs regardless of the MVA 
constructs employed. 
There were no clinical signs of disease nor lesions of any kind in the two nonvaccinated, 
nonchallenged control pigs. 
Virus isolations and titrations - Challenged nonvaccinates continued to shed virus 
through day 5 after challenge. In contrast, vaccinates, with the exception of the MVA/PR8 
IM group, shed on fewer days and at much lower titer (table 3). 
Serological assays - Serum HAI titers were higher in MVA/PR8 IM vaccinates than in 
the MVA/PR8 IN group, but this was not so evident in the MVA/SIV groups. Detectable 
titers did not appear in the MVA/SIV vaccinates until 14 days after the second vaccination. 
These were boosted by the SIV challenge as early as 5 days postchallenge, unlike those of the 
MVA/PR8 groups (table 4, figure 5). The SN titers for both MVA and SIV were very low 
prechallenge. At 5 days postchallenge, all vaccinated groups had some SIV SN titer 
developing (table 5). 
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Statistical analysis - The cumulative clinical sign score for the challenged nonvaccinated 
pigs was significantly greater than all other group scores (p<0.05), but the scores for the 
vaccinated groups were not statistically different from each other (table lb). The challenged 
nonvaccinated pigs had significantly more virus isolations than all groups (table 3), except 
those vaccinated IM with the MVA/PR8 recombinant. The MVA/PR8 IM and EN groups 
had a significantly greater number of isolations than the respective MVA/SIV IM and IN 
groups, but the two MVA/PR8 groups, as well as the two MVA/SIV groups, were not 
different from each other. Regarding titers of virus shed, the nonvaccinated controls had 
significantly greater titers than the MVA/SIV IN group on all 4 days of swabbing, the 
MVA/SrV IM and the MVA/PR8 EST groups on days 3-5, and the MVA/PR8 IM group on 
days 4 and 5 (data not shown). Analysis of the HAI titers indicates that, on the day before 
and 5 days postchallenge, titers of pigs vaccinated with MVA/PR8 IM are significantly 
greater than those for the MVA/PR8 IN group (table 4). However, there is no significant 
difference in titers between the two MVA/SIV groups for those days. For the serum 
neutralization titers, on day 5 postchallenge, each of the vaccinated pig groups had 
significantly higher titers than the nonvaccinated controls, but there were no significant 
differences between the vaccinated groups (table 5). 
Discussion 
The pathology induced by SFV occurs throughout the respiratory tract and consists of 
acute inflammation, edema, and bronchiolar epithelial necrosis Lung lesions tend to be 
bilaterally distributed, predominantly in the cranial and middle lobes. Generally, most pigs 
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recover but resolution of lesions may take up to a month. The MVA/SIV recombinant was 
eflBcacious in preventing these typical signs and lesions of SIV. 
In recent years, however, there have been periodic occurrences of 'atypical' SIV 
outbreaks, leading to speculation that the relatively stable antigenic profile of SIV may be 
changing. Reports have appeared in the literature since 1992, indicating the occurrence of 
SrV either associated with unusual signs or exhibiting more virulence than expected. First, 
there was a report fi'om Quebec regarding an HlNl variant producing proliferative and 
necrotizing pneumonia in pigs, with some signs very similar to those of the PRRS virus 
with more point mutations and diversity than generally seen in North American SIV 
isolates Another novel isolate, from a severely affected herd, was designated 
A/Sw/Nebraska/1/92 It induced persistent, high fevers (up to 42°C) but not much 
respiratory disease. Given the high degree of conserved sequences in typical SIV strains 
isolated in the U. S., it was surprising that the most closely related reference HlNl strain had 
only 94% identity at the nucleotide level and 96% at the amino acid level to this SIV isolate. 
Nonetheless, it  was closest genetically to 'classical '  HlNl SIV than to avian or human HlNl 
viruses. In England, an HlNl strain antigenically distinguishable from classic SIV and 
European avianlike HlNl viruses caused a sudden increase in SIV cases, but still exhibited 
the usual clinical signs of coughing, snee2dng, and anorexia However, upon experimental 
infection, this strain produced a more severe interstitial pneumonia and hemorrhagic lymph 
nodes. 
The significance of the genetic diversity represented by these strains is as yet 
undetermined. It may be that there are no 'atypical' SFV strains, merely a greater degree of 
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potential antigenic diversity among field strains than previously detected. It is known, 
however, that subtype HlNl influenza viruses have been continuously circulating in U. S. 
pigs for over 60 years. It is believed that the great pandemic of "Spanish flu" in 1918/19, the 
worst in history, killing at least 20 million people worldwide, was either caused by a swine 
virus or by a human strain that entered the pig population at that time In 1997, RNA from 
a casualty was extracted from formalin-fixed, parafiBn-embedded tissue and sequenced All 
sequences determined were very similar to those of classic HlNI SFV, suggesting that human 
and swine strains share a common avian ancestor, existing some time before 1918. The first 
isolation of SFV did not occur until 1930, however, and the 'classical' HlNl swine virus 
recovered (A/Swine/Iowa/15/30) is still much like the majority of SIV found circulating in 
U. S. pigs today. The ISU isolate from which HA and NP genes were cloned is 
representative of this subtype, as determined by sequencing. Given the results of our study, 
the MVA/SIV recombinant should provide protection against these strains. 
Northern Europe saw its first isolate of SFV in 1978/79, and although an HlNl virus, its 
HI was similar to the avian HI but distinct from both human and swine HI Since then, 
there have been instances where an avian virus has been able to cross species and infect the 
pig population, as with SwGer/81, and cases where reassortment between avian and classical 
SrV has occurred, as with SwHK/82 . In addition, there is a human virus-like H3N2 
subtype that has been isolated on occasion in European pigs since 1980, perhaps as a result of 
the 1968 antigenic shift and an ability of the H3N2 to persist in pigs even when not 
circulating in the human population It is interesting that a serological survey conducted in 
1988-1989 in U. S. pigs found evidence of H3 viruses antigenically similar to the then current 
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human H3 strains, at about 1.1% average prevalence In addition, a serological survey 
during 1976-1977 detected an incidence of 1.4% for H3N2 infections^. Moreover, in that 
study, isolation from one herd of a virus antigenically similar to a human H3N2 strain was 
reported- However, complete sequencing to determine whether the isolate was of human 
origin was not performed. So, no H3 human strain has been confirmed as present in U. S. 
pigs. Very recently, the National Veterinary Services Laboratories identified an influenza 
virus subtype H3N2 isolate from a swine breeding herd in North Carolina (interlaboratory 
communication). Studies are currently underway to determine species of origin and other 
characteristics of the virus. 
So, at the very least, there are three HA subtypes circulating in pigs at present, classic 
SrV HI, avian \arus-like HI, and human virus-like H3. They have been found in various 
permutations of SIV gene segments. One, an H3N1 strain, appeared to be a combination of 
the classic SFV and the human virus-like H3N2 found in swine "•*. Another, an H1N2 isolate 
believed to be from a human HlNl and the svme-adapted H3N2, caused clinical disease in 
pigs Still another represented a reassortment between human and avian strains in 
symptomatic Italian pigs, providing the first proof that pigs can act as 'mixing vessels' for 
human and avian viruses The critical role that pigs can play in pandemics was underscored 
with the discovery that children in the Netherlands were sick from avian-human influenza 
virus generated in pigs, transmitted pig-to-person, and person-to-person Normally, avian 
strains do not replicate in humans, and human strains do not replicate in birds. This is a 
fijnction of their specific sialyloligosaccharide receptors on the surface of epithelial cells of 
the upper respiratory tract. In a previous study, it was determined that, of 38 avian influenza 
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strains, fiiliy 31 were successfully transmitted to swine Every HA subtype (of 14 tested) 
had at least one strain that grew as well as a swine or human virus. Since then, it has been 
determined that pigs, in fact, have both avian- and human-specific viral receptors present in 
their upper respiratory tract and that some avian strains, with continued replication, acquire 
the ability to recognize human receptors as they become sAvine-adapted 
Taken together, these data delineate the danger to humans of a pig population 
unprotected against influenza. If an avian virus with a non-human-type HA is introduced into 
pigs, then reassorts with a human strain, a pandemic among complete susceptibles would 
occur. Although direct interspecies spread fi-om bird to human can happen, as was seen with 
the 1997 Hong Kong H5N1 cases virus under those circumstances may not 
readily adapt to its new host and relatively few may be affected. The dangers may be greater 
in the former scenario. 
In summary, interspecies transmission is known to occur and the pig, able to be infected 
by either avian or human strains can serve as a 'mixing vessel', wherein gene segments from 
different strains reassort to produce new viruses. Clearly, a safe, live vaccine vector able to 
express multiple genes, that could be given frequently to boost or provide new immunity, 
would be helpful. The recombinant MVA'SIV vaccine developed and evaluated in this study 
holds promise as a safe, effective means to protect pigs and people against typical U. S. 
strains of HlNl SFV. Even when the HA gene of the insert is heterotypic to an infecting 
strain, as was the case for the MVA/PR8 construct, immunity generated against the type A 
MP can help reduce clinical signs and clear virus more rapidly from vaccinated pigs. 
MVA may also be suitable as a vector for delivery of immunogens from other strains of 
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influenza. For repeated use of MVA in this capacity, it will be necessary to demonstrate that 
preexisting immunity to MVA or expressed proteins of one recombinant vaccine does not 
inhibit the immune response to a second recombinant vaccine. 
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-ss RNA 
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-SS RNA 
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JS5 • HA. NP 
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NP 
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G06 • NP-P-P-HA 
* i NPjiHA 
* screen by PGR, confirm by REA 
Figure I - Diagrammatic representation of the procedure used to insert flA and NP into 
plasmid vector G06 (-ss = negative sense single strand RNA; RT = reverse transcription; 
CloneAmp, JS5 = plasmid vectors, PP = double promoter in opposite orientation). 
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Figure 2 - A) G06 is a pUC-based vector containing flanking MVA sequences and double 
promoter (PP). With the insertion of NP and HA, restriction enzyme (RE) sites provide 
confirmation of proper orientation. B) Digestion of plasmid DNA with Smal, Bam HI, Pstl, 
and EcoRl results in the fi^agmentation pattern desired. 
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Figure 2 - Continued; C) Electrophoresis following RE digestion discloses the expected 
pattern. 
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NP HA 
G06-NP-HA 
(4 Clones) 
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• 
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> 6x 
Figure 3 - Representation of the procedure used for transfection of MVA-infected cells, 
passage on cells, and subsequent plaque purification for at least 6 rounds (IPA = 
immunoplaque assay, gpt = gpt selection media). 
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Figure 4 - A) Photomicrograph of a fixed and stained MVA/SIV plaque in an early stage of 
viral expansion. Primary antibody used was hyperimmune porcine-origin SIV antisera. B) A 
live immunostained MVA/SIV plaque (not fixed), also using hyperimmune porcine-origin 
SrV antisera as primary antibody. C) A fixed and stained MVA/SIV plaque, using HA-
specific monoclonal antibody. D) A fixed and stained MVA/SIV plaque, using NP-specific 
monoclonal antibody. Scale bar =100 microns. 
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Table 1 - A) Scoring of clinical signs during days 1-5 postchallenge. B) Results of scoring. 
A 
Clinical Signs to be Noted Points Given per Day 
Nasal and Ocular Discharge 
Serous 1 
Slight Mucopurulent 2 
Moderate " J 
Heavy 4 
Depression, Coughing, Sneezing, and 
Abnormal Breathing 
Mild I 
Moderate 2 
Severe -» J 
Gauntness, Dehydration 1 
Temperature > 104.5T 1 
B 
SIGN 
Cumulative Clinical Sign Score for Pigs in Different Groups 
CHALLC PR8 IM SIVIM PR8 IN SIV IN 
Nasal discharge 2 
Depression 30 2 
Coughing J 2 J 
Sneezing 11 I 1 4 
Abnormal Breathing 16 -» J 
Fever>104.5T 7 2 
TOTAL 69 8 1 9 0 
CHALL C = challenged nonvaccinated pigs; PR8 IM = MVA/PR8 IM vaccinates; SIV IM = 
MVA/SIV IM vaccinates; PR8 EST = MVA/PR8 IN vaccinates; SIV IN = MVA/SIV IN 
vaccinates. 
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Table 2 - Summary of results for lung lesions 5 days postchallenge in vaccinated and 
nonvaccinated pigs. 
Variable 
Pig Groups 
CHALL C PR8 IM srviM PR8 IN SIV IN 
# of pigs with gross 
lung lesions 6/6 6/6 0/6 6/6 2/6 
% of lung 
involvement 2-30 
< 10 
1 with 15 0 
<10 
I with 15 minimal 
presence of virus 
in the lung (by EHC) 6/6 
3/6 
small 
amount 
0/6 0/6 
2/6 
small 
amount 
histopathological 
lung lesions 6/6 6/6 1/6 6/6 3/6 
CHALL C = challenged nonvaccinated pigs; PR8 IM = MVA/PR8 EM vaccinates; SIV IM = 
MVA/SIV IM vaccinates; PR8 IN = MVA/PR8 IN vaccinates; SIV IN = MVA/SIV IN 
vaccinates. 
HC = immunohistochemistry. 
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Table 3 - Summary of results for viral isolation on days 2-5, nasal shedding on days 4 and 5, 
and titer of virus shed on day 4 postchallenge in vaccinated and nonvaccinated pigs. 
Variable 
Pig Groups 
CHALLC PR8 IM srviM PR8 IN SIV IN 
Cumulative virus 
Isolations 
Days 2-5 
6 pigs/group 
I swab/day/pig 
23/24 20/24 11/24 15/24 7/24 
# Shedding IN 
4 DPC 6/6 6/6 1/6 6/6 3/6 
# Shedding IN 
5 DPC 5/6 2/6 1/6 0/6 0/6 
Average (logio) 
IN titer (EIDso/ml) 
4 DPC 
J 2 0.8 1.5 0.5 
CHALL C = challenged nonvaccinated pigs; PR8 IM = MVA/'PRS EM vaccinates; SIV IM = 
MVA/SrV IM vaccinates; PR8 IN = MVA/PR8 EST vaccinates; SIV IN = MVA/SIV IN 
vaccinates. 
IN = intranasal; IM = intramuscular; DPC = days postchallenge. 
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Table 4 - Immune response in pigs as measured by geometric mean titer (GMT) of HAI 
titers; pig sera vs. PR8 and ISU influenza virus antigen 
Antibody Titer at Different Times 
Day 0 PVl 
c. 21 do 
14 DPVl 
Day 0 PV2 
-1 DAY PC 
c. 14 DPV2 
5 DAYS PC 
c. 56 do 
PIG 
GROUP 
# O F  
PIGS 
PR8 ISU PR8 ISU PR8 ISU PR8 ISU 
CHALL C 6 
- -
-
- - -
-
-
MVA/PR8IM 6 - - 22 - 508* - 452* -
MVA/SIVIM 6 - - - - - 57 - 113 
MVA/PR8IN 6 - - 2 - 27 - 34 -
MVA/SrVIN 6 - - - - - 40 - 160 
NEGC 2 - - - - nd nd - -
* On -1 and 5 days postchallenge, titers of pigs vaccinated with MVA/PR8 IM are 
significantly greater than those for the MVA/PR8 IN group. There is no significant 
difference in titers between the two MVA/SIV groups for those days. 
PVl = postvaccination 1; PC = postchallenge; PV2 = postvaccination 2; do = days old, 
CHALL C = challenged controls, NEG C = nonchallenged controls. 
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Figure 5 - Immune response in pigs as measured by geometric mean titer (GMT) of group 
hemagglutination mhibition (HAI) titers. This graph represents data found in table 4. 
Following second vaccination at day 14, the HAI titer rose markedly only for the group of 
pigs receiving the human flu recombinant IM. Following SIV challenge, there was an 
increase in titer for the pigs inoculated with MVA/SIV, but the titers for the MVA^RS IM 
group were not enhanced. 
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Table 5 - Immune responses in pigs as measured by geometric mean titer (GMT) of serum 
neutralization titers: pig sera vs. MVA and homologous SFV 
Antibody Titer at Different Times 
Day 0 PVI 
c. 21 do 
14 DPVl 
Day 0 PV2 
-1 DAY PC 
c. 14 DPV2 
5 DAYS PC 
c. 56 do 
PIG 
GROUP 
# O F  
PIGS 
MVA SIV MVA SIV MVA SIV MVA SIV 
CHALL C 6 - - - - - - - -
MVA>^R8 [M 6 - - - - 1.4 - 1.3 4.5 
MVA/SrVIM 6 - - - - - 2.1 1.3 7.0 
MVA/PR8IN 6 - - - - - - - 5.2 
MVA/SIV IN 6 - - - - - 1.3 - 3.9 
NEGC 2 - - - - - - - -
On Day 5 post challenge, each of the vaccinated pig groups had significantly higher GMT 
(p<0.05) than the nonvaccinated controls, but there were no significant differences between 
the vaccinated groups. 
PVl = postvaccination 1; PC = postchallenge; PV2 = postvaccination 2; do = days old, 
CHALL C = challenged controls, NEG C = nonchallenged controls. 
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3. EVALUATION OF INHIBITION OF IMMUNE RESPONSE TO VACCINATION 
FOLLOWING SEQUENTIAL USE IN PIGS OF TWO 
MODIFIED VACCINIA VIRUS ANKARA (MVA) RECOMBINANTS 
EXPRESSING HETEROLOGOUS INFLUENZA VIRUS GENES 
A paper to be submitted to Veterinary Microbiology 
P. L. Foley, 1. R. Stoll, S. K. Hanson, L. A. Wilbur, P. S. Paul 
Abstract 
The objective of this study was to detennine whether there is an inhibition in immune 
response to secondary vaccination, following sequential immunization with two vaccinia virus 
recombinants. The recombinants were constructed from the highly attenuated modified 
vaccinia virus Ankara strain (MVA), and contained the hemagglutinin (HA) and 
nucleoprotein (NP) genes of either a human strain or a porcine strain of influenza virus. 
Sixteen colostrum-deprived, caesarean-derived pigs were divided into three groups. One 
group of six was immunized with the recombinant human influenza virus vaccine 
intramuscularly (IM) and another group of six received it intranasally (IN) at both 21 and 35 
days of age. Four pigs served as unvaccinated controls. At 91 and 105 days of age, all 16 
pigs were administered EM the recombinant vaccine virus containing the swine influenza virus 
(SrV) HA and NP. Blood samples were collected at 2-week: intervals through 23 weeks of 
age, and tested for antibodies by hemagglutination inhibition (HAI) against both strains of 
influenza virus and by serum neutralization (SN) with MVA and SIV. There was no 
significant inhibition of neutralizing antibodies during the study. Secondary SIV HAI 
responses were significantly greater following initial IN vaccination. Serum titers that 
developed against the human influenza virus, PR8, did not prevent development of SIV titers. 
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This suggests that sequential use of such recombinants containing inserts from various strains 
may be successful in practice. 
1. Introduction 
The advent of recombinant vaccines capable of expressing numerous foreign inserts has 
raised the question of whether frequent use of such constructs to deliver different antigens 
might be inherently nonproductive (Etlinger & Altenburger 1991; Flexner, et al. 1988; 
Rooney, et al. 1988). Would, in fact, preexisting immunity to the virus adversely affect 
efficacy? It has been thought by some that the immune response generated against a vector 
would limit its replication and prevent adequate expression of the inserts. This, in turn, 
would inhibit the induction of protective immunity against the heterologous proteins. In 
support of this view, one study (Chelyapov, et al. 1988) demonstrated the strength of the 
immune response to W. It showed that antibodies were generated against most of the 
vaccinia virus (W) structural proteins, including those proteins located internally within the 
virus, in both rabbits and humans, that these antibodies in humans were preserved over many 
years, and that insertion of foreign genes did not affect this pattern. Additional reports 
indicated that preexisting immunity to W resulted in reduced titers of antibody to the foreign 
protein (Cooney, et al. 1991; Rooney, et al. 1988), decreased protection (Rooney, et al. 
1988), and reduced, transient T-cell response (Cooney, et al. 1991). Another study (Kundig, 
et al. 1993) demonstrated that vaccination with one W recombinant resulted in long term 
suppression of the humoral response in mice to a second W recombinant's gene product. 
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On the other hand, there have been reports of boosting antibody titers in animals given the 
same recombinant virus, or of induction of immunity against a foreign antigen in animals 
vaccinated with W subsequently inoculated v^th a recombinant W expressing that antigen 
(Etlinger & Altenburger 1991; Jones, et al. 1986; Perkxis, et al. 1985; Rooney, et al. 1988). 
Also, antibody titer to one of the heterologous proteins in a multivalent W recombinant did 
not prevent mice from developing immunity (Rexner, et al. 1988). Still, questions have 
persisted about the adequacy of the response in these cases, even if outright suppression has 
not occurred. 
To avoid interference to secondary vaccination and improve the immune response, some 
have tried using diversified prime and boost regimens for vaccinations, as in priming with a 
W recombinant, followed by a subunit vaccine containing the expressed protein. Use of a 
subunit as booster has met with mixed results (Cooney, et al. 1993; VIontefiori, et al. 1992). 
In one study, use of a W recombinant, boosted by a recombinant avian pox virus, resulted in 
improved T-cell responses, better than when using either construct alone (Hodge, et al. 
1997). In another study, mice primed with an influenza virus recombinant and boosted with a 
W construct expressing the same antigen developed strong secondary antigen-specific CD8' 
T cell responses, but only if the vaccines were given in just that order. However, these 
regimens are not appropriate for achieving widespread prophylaxis and therapy on a 
commercial scale. From a practical standpoint, the preferred alternative would be to have 
just one vector, capable of being used safely and repeatedly to express numerous inserts. 
In the present study, the concept of repeated use of the same W vector containing 
different inserts was explored. Unlike other studies, however, the vector chosen was the 
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modified vaccinia virus Ankara (MVA) strain, which was safely used in over 120,000 people 
during the smallpox eradication program, and which has been well characterized (Bender, et 
al. 1996; Carroll & Moss 1997; Carroll, etal. 1997; Meyer, et al. 1991; Sutter & Moss 1992; 
Sutter, et al. 1994; Wyatt, et al. 1996). MVA has been used successfully in the past as a 
vector for influenza virus structural proteins in mice (Bender, et al. 1996; Sutter, et al. 1994), 
parainfluenza virus 3 proteins in cotton rats (Wyatt, et al. 1996), and simian 
immunodeficiency virus env-gag-pol in macaques (Hirsch, et al. 1996). It was also able to 
protect against and provide therapy for pulmonary metastases in mice (CarrolL et al. 1997). 
The MVA strain is replication-incompetent in most all mammalian cells tested, a consequence 
of six major deletions equal to 15% of its genome that prevents virus assembly but leaves 
gene expression, both early and late, relatively unimpaired. This feature could presumably 
allow repeated use of the vector with little induction of inhibiting levels of anti-vaccinia virus 
antibody. If a protective immune response could be generated against an inserted protein, 
even following repeated use of the MVA vector, then the value of MVA as a delivery system 
for immunogens would be increased. 
To conduct this study, two MVA recombinants were used. The first of these contains the 
HA and NP genes fi'om the HlNl human influenza strain, A/PR/8/34 (PR8), in opposite 
orientation and under the control of two optimized synthetic early/late promoters. This 
construct has been shown to provide protection to mice against a lethal challenge from PR8 
(Sutter, et al. 1994). The second MVA-vectored recombinant, using the same promoters, 
expresses the HA and NP genes from a type A HlNl field strain of swine influenza virus 
(SIV). These gene inserts were chosen because previous studies have demonstrated that HA 
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induces virus-neutralizing antibody, important for protection against infection (Webster, et al. 
1991); and that NP is the major target antigen recognized by type-specific cross-reactive 
cytotoxic T-lymphocytes (CTL) (Townsend & Skehei 1984; YewdeU, etai 1985), 
responsible for recovery firom infection (Wraith, et al. 1987). 
Since most of the protective humoral response following exposure to influenza virus is 
generated against the five hypervariable antigenic sites of HA, antibodies to this protein 
provide immunity to influenza viruses with a sufficiently similar HA (Andrew, et al. 1987). 
In a previous study at our laboratory, it was determined that the PR8 HA is not homologous 
enough to the SIV HA for their respective antibodies to be cross-reactive on serological 
assays (Foley et al, manuscript in preparation). This lack of reactivity allows, in the present 
study, an opportunity to evaluate MVA antibody interference, using identical test 
methodology to determine antibody response against heterologous gene inserts. 
The optimal route of vaccine delivery for a respiratory pathogen, such as influenza, has 
been a matter of some discussion. One study (Small, et al. 1985) found that intranasal (IN) 
administration of a W recombinant expressing HAl in mice protected both lung and nose 
against homologous challenge, but scarification protected only limg. Another group (Meitin, 
et al. 1991) vaccinated mice either intraperitoneally (IP) with a killed PR8 vaccine, 
stimulating high serum IgG, or IN with a W recombinant containing HAi, inducing nasal 
IgA titers. They found that the lungs but not noses in the IP group and the noses but not 
lungs in the IN group were fiiUy protected against challenge. By reversing protection in mice 
recovered fi-om infection with influenza, using anti-IgA antiserum, it has since been shown 
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that IgA is the primary factor in nasal immunity to influenza virus in mice (Renegar & Small 
Jr. 1991). To maximize both IgA. and IgG, several studies have tried to stimulate the 
'common mucosal immune system' (Czerkinsky & Svermerholm 1993; Yetter, etal. 1980) in 
mice by intragastric or intrajejeunal administration of a W or MVA recombinant expressing 
influenza virus genes (Bender, et al. 1996; Meitin, et al. 1994). They, in fact, have been 
successful in attaining mucosal IgA, serum IgG, and CTL activity. However, the use of 
orally-administered enteric-coated capsules is not a viable option for weanling pigs, at this 
time, though they hold great promise for human vaccination programs. Consequently, the 
pigs used in this study were inoculated either intramuscularly (IM) or IN, to evaluate the 
effect these routes might have on inhibition of secondary vaccination. 
2. Materials and methods 
2.1 Cells and Viruses including MVA recombinants 
Vaccinia virus strains MVA and the MVA recombinant expressing PR8 HA and NP genes 
(MVA/PR8) were generously provided by B. Moss, Laboratory for Viral Diseases, National 
Institute of Allergy and Infectious Diseases (NIAED), National Institutes of Health (NIH). 
The MVA recombinant expressing SIV HA and NP genes (MVA/SFV) was recently 
constructed in our laboratory (Foley et al., manuscript in preparation) from an Iowa field 
strain of SIV isolated by the Iowa State University Veterinary Diagnostic Laboratory 
(courtesy of B. Janke). MVA, MVA/PR8, and MVA/SIV were grown at 37°C and 5% CO, 
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in the second passage of chicken embryo fibroblast cells, using M199 medium with F-10 
nutrient mixture (M199/F-10), supplemented with 0.15% bactotryptose phosphate broth, 
0.09% Na bicarbonate, 1% L-glutamine, 25 U/mi penicillin G potassium, 75 U/ml 
streptomycin sulfate, 0.1% gentocin, and 5% FBS. 
A 1960's SrV field isolate of the 'classical' swine HlNl subtj^je, provided by the 
Diagnostic Virology Laboratory (DVL), National Veterinary Services Laboratories (NVSL); 
a reference 'classical' HlNl virus, A/Sw/IN/1726/88, provided by Virginia Hinshaw, 
University of Wisconsin; and the ISU field isolate were propagated allantoically in 10-day-oId 
embryonated chicken eggs at 37°C for 72 hours, and titrated by mean egg infectious dose 
(EID30) and hemagglutination (HA) units. In addition, several cell lines, including Madin-
Darby Canine Kidney (MDCK), swine testicle (ST), porcine kidney (PK-15), and another 
dog kidney line (DK-F), were tested for their ability to support SIV growth, with and without 
the use of centrifiigation and trypsin, using the three strains of SIV. It was determined that a 
24-hr-old ST monolayer, seeded at 2 x 10^ cells/ml, and grown at 37°C, in 5% CO,, using 
Minimum Essential Medium (MEM) with Earle's salts (Gibco cat. no. 41500-018), 
supplemented with 0.22% Na bicarbonate, 0.5% edamine, 1% L-glutamine, 25 U/ml 
penicillin G potassium, 75 U/ml streptomycin sulfate, 0.1% gentocin, 1% sodium pyruvate, 
and 5% FBS, provided good conditions for SIV replication (data not shown). At 24 hours 
afl;er seeding, medium was decanted and the ST monolayer inoculated with virus in sufficient 
medium to cover the monolayer. Following virus adsorption for one hour at 37°C, fi^esh 
medium was added and the cultures incubated at 37°C in 5% CO,. 
2.2 Titration of viruses 
120 
For MVA and MVA recombinant virus titrations, 24-hour old CEF cells, seeded at 8 x 10^ 
cells/ml in 60 millimeter (mm) tissue culture plates under conditions cited above, were 
decanted then refed with new media containing only 1% FBS, inoculated with 100 ul/well of 
serial 10-fold dilutions of virus, incubated at 37°C in 5% CO,, then fixed at 2 days 
postinfection. MVA recombinant-inoculated plates were fixed in 1:1 acetone:methanol, 
reacted with primary antibody, then anti-mouse or anti-swine peroxidase-labeled conjugate. 
The substrate used for these assays was metal enhanced DAB (Pierce, Rockford, EL). 
Recombinant virus titers were determined using insert-reactive anti-HlNl SIV polyclonal 
antisera and anti-PR8 HA and NP monoclonal antibodies (courtesy of J. Yewdell, NIAID, 
NIH) as primary antibody, and expressed as plaque-forming units (PFU). MVA titers were 
determined using either cytopathic effect (CPE) or immunofluorescent assay (IFA.). For the 
latter procedure, the plates were fixed in 80% acetone. The primary antibody was a rabbit-
origin anti-W polyclonal antisera, reacted vsnth an anti-rabbit FITC-conjugate, with titers 
expressed as fluorescent focal units (FFU). This EFA procedure was also used on the MVA 
recombinant-infected plates, subsequent to the DAB immunoplaque assay, to determine the 
titer of non-expressing plaques. 
For SIV titration on the ST cell line, 96-well plates were inoculated with 50 ul virus 
dilution per well, centrifiiged at room temperature for 2 hours at 400xg, incubated at 37°C in 
5% CO2, then read by CPE or EFA, using anti-HlNl SIV polyclonal antisera, 5-7 days 
postinoculation. 
2.3 Animal Immunizations 
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16 colostmm-deprived, caesarean-derived pigs (CDCD) were divided into 3 groups. One 
group of 6 received 1 mi of c. lO^PFXJ of the MVA/PR8 recombinant IM along with an 
additional c. 1.7 logio FFU of MVA not expressing the insert; another group of six received 
the same inoculum EN in 2 ml (diluted 1:1 in 0.01 M PBS, pH 7.2, 1 ml per nostril) at both 21 
and 35 days of age. The IN inoculations were administered using a gas-powered atomizer, as 
previously described (Sinclair & Tamoglia 1972). Four pigs remained unvaccinated until 91 
and 105 days of age, when all 16 pigs were administered 1 ml of c. 10^ PFU of the MVA/SIV 
recombinant IM, along with c. 0.1 logio FFU of non-insert-expressing MVA. 
2.4 Serological assays 
Serum samples were harvested at 2-week intervals beginning at 21 days of age, through 
161 days of age, then analyzed by hemagglutination inhibition (HAI) against the two strains 
of influenza virus, PR8 and ISU, and by serum neutralization (SN) of MVA and SIV, using 
the constant virus-varying serum method. 
HA and HAI tests were performed in 96-well microtiter plates, using 0.5% chicken 
erythrocytes. For the SIV and PR8 HAI assay, sera were pretreated using 10% kaolin and 
5% washed chicken erythrocytes, then evaluated at 1:10 or greater dilutions against 
standardized live virus antigen. For these assays, four HA units of each virus were used to 
determine serum HAI titers. 
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The MVA SN procedure used 96-weIl plates containing 24-hour-old monolayers of CEF 
cells, inoculated with 50 ul of a 1:1 mixture of virus and 5-fold dilutions of serum, previously 
incubated at 37°C for 1 hour. Back titration established virus titer at 100-200 mean tissue 
culture infectious dose (TCID50). The inoculum was decanted after 1 hour, replaced with 
200 ul of M199/F-10 media, supplemented as above but with only 0.5% FBS, and read at 5-7 
days by CPE. SN titers were determined by the method of Reed-Muench (Reed & Muench 
1938; Schmidt & Emmons 1989). 
The SIV SN procedure, except for the use of the ST cell line, a different maintenance 
medium (MEM and Earle's salts with no FBS), and centrifugation as described above, is 
otherwise the same as that used for the MVA SN assay. The DVL strain of SFV, because 
better adapted to cell culture, was utilized in SN assays at 70-250 TCID50. 
2.4 Statistical analysis 
For comparison of data between groups within a given table and between MVA/PR8 EM, 
day 0 to 70 on Table la, and MVA/SIVIM, day 70 to 140 on Table lb (HAI titers), an 
analysis of variance (ANOVA) was conducted. The means were compared using the Least 
Significant Difference (LSD) method. For all correlation statistics, the correlation coeflBcient 
was based on the logarithms of the HEAI and SN titers. To determine geometric mean titer 
(GMT), logio of each titer was summated, then averaged and the antilog determined. 
Because negative titers are '0', 1 was added to all numbers, then subtracted later firom the 
averaged GMT. 
2.5 Sequence analysis 
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The ISU SrV HA and NP genes have been previously cloned and described (Foley, et aL, 
manuscript in preparation), but their nucleotide sequences have not been previously reported. 
The cloned genes were subjected to primer walking along both strands of DNA, starting with 
the Universal (-21M13) and Reverse CR-2', M13-USB) primers, using the ABI Prism Model 
377 DNA Sequencer (Perkin Ebner). Sequences generated were aligned, edited, and 
assembled using AutoAssembler (Perkin Elmer). HA and NP sequences from PR8 and 
A/Sw/IN/I726/88 (IN88), a 'classical' t5T)e A HlNl SIV, were retrieved from the GenBank 
database using the respective accession numbers for PR8 HA (J02143) and NP (J02147), and 
IN88 HA (M81707) and NP (L46849). Sequences were compared using Omiga 1.1 software 
(Oxford Molecular Group). Slight alterations, consisting of a single base addition, were 
made in the retrieved sequences only when needed to preserve the reading frame. In one 
case, addition of a single 'T' at IN88 HA base 1629, converted an otherwise meaningless 
amino acid code into one that closely followed the code for ISU HA for the remainder of the 
protein sequence. Likewise, an apparent missing base at nucleotide 1630 in PR8 HA 
rendered the bases thereafter totally heterologous. If a 'missing' G (found in ISU and INS 8 
HA) is added, the homology is 83.4% up to amino acid 556, when the code again becomes 
scrambled. If the first 1629 bases (or 543 amino acids) only are compared, that is, without 
adding the G, then the amino acid homology is 83.1%. It was felt that this was close enough 
to the first figure to call at 83% homology. 
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3. Results 
3.1 Serological responses 
Examination of tiie HAI titers against the PR8 strain over the 140-day study indicates no 
cross reactivity with the ISU strain, in that PR8 titers were not enhanced after inoculation 
with MVA/SrV on days 70 and 84 (Table 1, Figure 1). In fact, HAI titers among the 
MVA/PR8 IM group continued to decline. Also, the MVA/PR8 IM titers are considerably 
higher than in the IN group after the initial vaccinations. 
Following subsequent IM vaccination in all 16 pigs with MVA'SIV, HAI titers against ISU 
rose faster and higher (p<0.05) in the pigs previously vaccinated EN with the MVA/PR8 
recombinant (Table2, Figure 2). The increase is similar to that seen in the MVA/PR8 IM 
group following vaccination with MVA/PR8 by IM route on days 0 and 14 (Table 3). 
There is no detectable SN titer against MVA in the MVA^R8 IN group until two weeks 
after administration of the first MVA/SIV inoculation (Table 4, Figure 3). Even then, those 
MVA SN titers are less than in pigs having received MVA'PRS by IM route (p<0.05). The 
MVA SN titers in the MVA/PR8 IM group appear by two weeks after the second MVA'PRS 
vaccination, and are boosted by the MVA/SIV injections on days 70 and 84. 
The SN titers against SFV are not apparent until two weeks after the first MVA/SIV 
vaccination (Table 5, Figure 4). At that time there is no significant difterence in SN between 
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pigs previously vaccinated either IM or IN with the MVA/PR8 construct, but both groups 
have a significantly greater response than those in the control group vaccinated only with 
MVA/SIV (p<0.05). 
3.2 Statistical analysis 
The PR8 HAI titers of the MVA/PR8 IM group fi-om day 0 to day 70 (Table 1) show a 
similar rise in HAI titer and, in fact, are not statistically different using ANOVA/LSD 
methodology, fi-om the ISU HAI titers of the MVA/PRS group from day 70 to day 140, 
following MVA/SrV IM vaccination (Table 2). A qualitative representation, comparing the 
relative immune responses of the groups, is depicted in Table 3. Also, there is no negative 
correlation between MVA SN titers (Table 4) and ISU HAI titers (Table 2) for days 84 to 
140, that is, a higher MVA SN titer is not associated with a lower ISU HAI titer. Regarding 
the SIV SN titers (Table 5), both the IM and EN groups were significantly (p<0.05) greater 
than the control group but not different fi-om each other. 
3.3 Sequence analysis 
The ISU HA gene had 98% homology to the IN88 HA at the nucleotide level, but only 
81% to the PR8 HA (Table 6). This represented 99% homology at the amino acid level 
between ISU and IN88 HA, but only 83% to the PR8 HA. Regarding comparison of NP, 
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ISU and INSS shared 96% nucleotide and 99% amino acid similarity; the PR8 NP, when 
compared to that of ISU, showed 87% nucleotide and 92% amino acid homology. The 
differences between the two genes of IN88 and ISU (figures 5a, 5b, 5c) did not appear to be 
at locations previously associated with changes in virulence, such as the cleavage site 
between the HI and H2 portions of the HA gene (Senne, et al. 1996). 
4. Discussion 
Both the MVA/PR8 IN and IM groups seem to have a rise in SIV SN titer following 
MVA/SrV IM inoculation, not shared by the controls. It may be that a nonspecific immune 
stimulation due to previous vaccination occurred. This phenomenon, or some other, such as 
better priming of T helper cells, may be at play in the HAI titers against ISU, wherein the IN 
group titers appear to be increased when compared to those of the control and IM groups. 
The IM group HAI titers are equivalent to those of the nonvaccinated controls and, thus, do 
not suggest interference. Yet, one might argue that the EM group titers are not as high as 
those of the IN group due to interference firom higher anti-MVA IgG titers, as suggested by 
the IM group's higher MVA SN titers. However, it cannot truly be said to be interference if 
the titers achieved are the same as those realized in naive animals. What's more, the ISU SN 
titers for the IM and IN groups are not significantly different, though statistically greater than 
the controls. The expectation would be that any interference would result in a decreased 
ability to neutralize virus. Instead, neither MVA nor SIV SN immune responses showed 
significant inhibition during the study (p<0.05). Lastly, and of great importance, the 
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development of HAI titers against PR8 had no detectable effect on the development of HAI 
titers against the ISU strain. 
Sequence analysis of the ISU and PR8 HA and NP genes indicates that, whereas the type 
A-specific NP gene is fairly homologous (87% nucleotides, 92% amino acid residues), the 
more strain-specific HA gene is suflBciently heterologous (only 81% nucleotides are the same, 
83% amino acids) to explain the lack of cross-reactivity on HAI assay. Sequential 
vaccination with such heterologous constructs should allow for independent titers, not 
inhibited by MVA titers. For more homologous constructs, the effect would seem to be, 
from the results seen here of several vaccinations, simple boosting. 
Previous studies using replication-competent W strains have demonstrated interference 
caused by preexisting immunity to the W vector (Cooney, et al. 1991; Kundig, et al. 1993; 
Rooney, et al. 1988). Presumably, the ability of these MVA recombinants to vector different 
inserts without secondary vaccination inhibition is due to MVA's host restriction. The 
supposition would be that, by not generating too strong a response, subsequent vectored 
vaccines are not overv^'helmed. This hypothesis should be tested further with different inserts 
and varied vaccination regimens. 
One concern related to vaccination interference has been that, even where anti-W 
antibody has little effect on the antibody response to a foreign gene product, there may still 
be interference from pre-existing maternal antibody to the virus from which the protein 
derives. Some have noted that passively administered polyclonal antibody to a foreign 
protein can inhibit B-cell response to a W recombinant vaccine, but not necessarily the 
cytotoxic T-lymphocyte response (Galletti, etai 1995; Johnson, et al. 1993). One study 
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(Brockmeier, et al. 1997) found that, of two W recombinants expressing one of two 
pseudorabies glycoproteins, only one protected similarly regardless of the presence of 
maternal antibody, suggesting that choice of insert can be crucial to induction of immunity. It 
would be interesting to see if the replication-incompetent MVA can improve protection in the 
face of maternal passive immunity. 
Researchers have reported success in culturing influenza viruses in various cell lines, 
including MDCK (Hinshaw, et al. 1994). In our hands, the ST cell line allowed for titration 
of SrV by both CPE and BFA, as did the DK-F line. The PK-15 cell line did not demonstrate 
apparent cytolytic effect upon infection with SIV, but virus replicated as evidenced by IF A. 
In our laboratory, the MDCK line did not indicate the effects of SIV infection as readily or 
reliably when compared to the other cell lines. 
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Table 1 
Immune responses in pigs against PR8 strain, as measured by hemagglutination inhibition 
Geometric mean HAI titers at days post first inoculation with IV1VA/PR8 
Group n 0» 14'' 28 42 56 70*^^ 84" 98 112 127 140 
IN ' 6 neg neg 0.5 0,5 0,5 2,7 1,2 1,2 2,7 2,3 0.5 
IIM 6 neg 4,1 89,9 36,0 25,6 11.1 6.7 5,9 5,9 5,9 5,2 
Control 4 neg neg neg neg neg neg neg neg neg neg neg 
12 pigs were inoculated with MVA/PR8 recombinant, either IN or IM, Four controls did not receive 
the MVA/PR8 inoculum, 
all pigs, including the 4 controls not yet inoculated, were given the MVA/SIV recombinant by the IM 
route. Up through day 140, the last day of testing, the 4 controls had no detectable HI titer (< 10) 
against the PR8 strain of influenza virus, 
HAI: hemagglutination inhibition, n; number in group, 
neg: geometric mean titer = 0, 
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Figure 1. Immune response of pigs represented by GMT of group HAI titers against the 
PR8 strain of influenza virus. This graph corresponds to the data found in table 
1. The response in the PR8 IM group was greatest, and was not stimulated by 
vaccination with MVA/SIV on days 70 and 84. 
Table 2 
Immune responses in pigs against ISU strain, as measured by hemagglutination inhibition 
Geometric mean HAI titers at days post first inoculation with MVA/PR8 
Group n 0" 14" 28 42 56 84' 98 112 127 140 
IN 6 neg neg neg neg neg neg 9.2 71.3 44,9 40,1 25,2 
IM 6 neg neg neg neg neg neg neg 14,8 9,2 8,1 11,2 
Control 4 neg neg neg neg neg neg neg 20,0 11.9 11,9 5,0 
12 pigs were inoculated with MVA/PR8 recombinant, either IN or IM, Four controls did not receive 
the MVA/PR8 inoculum, 
°''' all pigs, including the 4 controls not yet inoculated, were given the MVA/SIV recombinant by the IM 
route, 
HAI: hemagglutination inhibition, n: number in group, 
neg: geometric mean titer = 0, 
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Figure 2. Immune response of pigs represented by GMT of group HAI titers against the 
ISU strain of influenza virus. This graph corresponds to the data found in table 
2. The response was greatest in the group having received the MVA/PR8 
vaccine IN. 
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Table 3 
Qualitative representation of HAI response to vaccinations on days 0, 14 with 
MVA/PR8 and days 70, 84 with MVA/SIV 
ROUTE OF 1ST 
VACCINATION 
RESPONSE TO 1ST 
VACCINE (MVA/PR8) 
RESPONSE TO 2ND VACCINE 
(MVA/SIVgiven IM) 
IN + +++ 
DVI +++ -H-
NONE - ++ 
+ = weak, ++ = moderate, +++ = strong. 
HAI = hemagglutination inhibition. 
Table 4 
Immune responses in pigs, as measured by ability to neutralize the vaccinia virus MVA 
Geometric mean SN titers at days post first inoculation with MVA/PR8 
Group n 0" 14" 28 42 56 70*^ 84" 98 112 127 140 
IN 6 neg neg neg neg neg neg 5,2 2,0 2,7 3,2 3,7 
IM 6 neg 0.3 8.6 1,4 1,6 0,3 28,3 17,2 28,1 22,8 15,1 
Control 4 neg neg neg neg neg neg neg neg neg neg neg 
12 pigs were inoculated with MVA/PR8 recombinant, either IN or IM, Four controls did not receive 
the MVA/PR8 inocuium, 
all pigs, including the 4 controls not yet inoculated, were given the MVA/SIV recombinant by the IM 
route. Up through day 140, the last day of testing, the 4 controls had no detectable titer (< 5) against 
MVA. 
SN: serum neutralization, n: number in group. 
neg: geometric mean titer = 0, 
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Figure 3. Immune response of pigs represented by GMT of group SN titers against the 
MVA strain of vaccinia virus. This graph corresponds to the data found in table 
4. The response in the previously vaccinated groups, as measured by virus 
neutralization, was increased following vaccination vi^ith the second recombinant. 
Table 5 
Immune responses in pigs, as measured by ability to neutralize homologous SIV 
Geometric mean SN titers at days post first inoculation with MVA/PR8 
Group n 0" 14" 28 42 56 70' 84" 98 112 127 140 
IN 6 neg neg neg neg neg neg 5,2 14,6 14,5 22,6 21,2 
IM 6 neg neg neg neg neg neg 6,2 7,3 11,6 12,1 12,1 
Control 4 neg neg neg neg neg neg neg 2,0 2,0 3.2 2,5 
12 pigs were inoculated with MVA/PR8 recombinant, either IN or IM, Four controls did not receive 
the MVA/PR8 inoculum, 
all pigs, including the 4 controls not yet inoculated, were given the MVA/SIV recombinant by the IM 
route, 
SN: serum neutralization, n: number in group, 
neg: geometric mean titer = 0, 
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Figure 4. Immune response of pigs represented by GMT of group SN titers against a 
homologous HlNl strain of SFV. This graph corresponds to the data found in 
table 5. The response in the vaccinates, as measured by virus neutralization, was 
significantly greater than in the controls. 
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Table 6 
Nucleotide (NT) and amino acid (AA) homology of HA and NP genes of ISU SIV isolate 
with those of PR8 and IN88 isolates 
Influenza 
virus gene 
% Homology With 
ISU SIV HA ISU SIV NP 
NT AA NT AA 
PR8HA 81 83 - -
PR8 NP - - 87 92 
IN88 HA 98 99 - -
IN88 HP - - 96 99 
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Sequence Differences 
SW/IN/1726/88 vs. ISUDL 
Amino Nucleic 
Acids Acids 
HI (1032 bp): 0 13 
H2(692bp): 4 17 
NP (1490 bp): 3 53 
B 
HA Amino Acid Differences 
in S74 AAs 
m -H2 cleavage at #344-345 
AA Residue IN/88 ISUDL 
403 valine isoleucine 
491 threonine lysine* 
505 aspcu-agine lysine* 
549 glycine serine 
* basic AAs 
NP Amino Acid Differences 
in 1490 NTs or 496 AAs 
AA Residue IN/88 ISUDL 
316 valine isoleucine 
450 asparagine serine 
482 asparagine serine 
Figure 5 - Sequence differences between the HA and NP genes of two SIV isolates. 
A) Although there is some diversity at the nucleotide level, the changes are nonessential. 
When translated, there are few amino acid (AA) differences between the two strains, the 
classic IN/88 and the ISU Diagnostic Laboratory (ISUDL) isolate. B) The ISUDL strain, 
from which the HA and NP genes were cloned, has a few more basic amino acids, but they 
are not at the cleavage site between HI and H2. An increase in the basic amino acids, lysine 
and arginine, at that location has been associated with increased virulence (Senne et al, 
1996). C) The amino acid changes between the two NP proteins are few and apparently not 
significant. 
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GENERAL CONCLUSIONS 
The first study undertaken in this thesis project demonstrated that the immunity 
provided by MVA/PR8 was incomplete against SIV infection, clinical disease, and virus 
shedding. The second study indicated the marked improvement in protection against 
homologous SrV challenge when pigs were vaccinated with the MVA/SFV construct. The 
third study provided evidence that sequential use of such MVA recombinants containing 
inserts fi-om various strains of influenza, given a mere two months apart, still generated 
appropriate immune responses to the different inserts. Taken together, the data underscore 
the suitability of the MVA vector to express immunogens in a safe, efficacious, and 
reproducible maimer. Although there is an inactivated SIV vaccine commercially available, 
there are numerous advantages to using a live recombinant vaccine. For one, the foreign 
protein expressed by the recombinant moves through the Class I pathway and is appropriately 
presented to cytotoxic T cells, priming cell-mediated immunity (Bermink, et al. 1984; 
Blancou, et al. 1986; Cremer, et al. 1985; Earl, et al. 1986; Morrison, et ai 1986; Panicali, et 
al. 1983; Paoletti, et al. 1984; Smith, et al. 1983; Yewdell, etal. 1986). Second, vaccination 
with recombinant W can stimulate even an impaired immune system. For example, it has 
been shown that old mice, like elderly humans, are more susceptible to influenza despite 
immunization with killed vaccines. However, when vaccinated with a W recombinant 
containing the PR8 HA gene, they were protected from challenge and generated high levels 
of anti-HA Ab and PR8-specific cytotoxic T cells (Ben-Yehuda, et al. 1993). Third, the 
capacity of MVA or W to hold numerous inserts provides an opportunity for one construct 
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to protect against the entire range of SIV HA molecule diversity, as well as induce type-
specific immunity using the NP gene. Fourth, if our vaccination/inhibition data holds true for 
other antigens, the MVA vector can be used to carry a variety of inserts, with repeat 
vaccination as early as two months after the first recombinant regimen. Fifth, a number of 
studies indicate that killed vaccines do not provide as long lasting protective immunity 
(Askonas, et al. 1982; Ben-Yehuda, et al. 1993), when compared to attenuated and 
recombinant live vaccines. 
The characteristics of an ideal viral vaccine have been listed previously 
(Paul 1998) and include: protection against disease, protection against infection, protection 
against multiple serotypes, long lasting immunity, safety for the host animal, little to no virus 
shedding, no reversion to virulence, and differentiation of vaccinated animals from those 
exposed to wildtype virus. In the present studies and others, the case is being made for MVA 
as an ideal vaccine vector. MVA recombinants are able to protect against disease and 
infection, and potentially against multiple serotj^es. MVA is safe for mammalian hosts, does 
not result in shedding nor reversion to virulence, and vaccinates can be distinguished from 
exposed animals. What is not yet determined is the duration of immunity provided. 
What remains for near future testing, then, is determination of how long immune 
response to MVA recombinants endures. Studies should also be conducted to establish 
optimum dose and time for vaccination, and whether maternal Ab interferes with 
immunization. In addition, it would be helpful to know which days postchallenge, of days 1 
through 5, SIV can be isolated from the lungs, especially of IM-inoculated vaccinates. The 
lack of lesions on day 5 postchallenge in this group, the low level of virus present in the 
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nares, and the absence of clinical signs suggests that the systemic IgG response is potent and 
keeps viral replication in check. This hypothesis should be verified by cell culture and 
immunohistochemistry. Lastly, the prevalence and distribution of naturally occurring 
orthopoxviruses, especially in small mammalian species, should be assessed, as was done in 
Norway (Sandvik, et al. 1998), and the ability of various vaccine vectors to recombine with 
them determined. Given that the MVA strain is replication-incompetent in mammalian cell 
lines, there would appear to be little to no chance for recombination to occur if it is 
administered by IM inoculation. Likewise, the possibility of reassortment of influenza RNA 
segments seems remote, given that MVA is a DNA virus residing in the cytoplasm, producing 
positive sense mRNA for protein production. In contrast SIV is a negative-sense RNA virus 
residing in the nucleus, but only of epithelial cells of the respiratory tract (Easterday & 
Hinshaw 1992; Enami, et al. 1991; Murphy Webster 1996; Whittaker & Helenius 1998), 
making reassortment of recombinant and influenza RNA very unlikely if the MVA vaccine is 
given EN, and impossible if the vaccine is given IM. Although it is theoretically possible for 
IN-inoculated MVA-expressed HA and NP protein to be incorporated into co-infecting SIV 
replication, use of the IM route, more advantageous for other reasons, such as ease of use, 
completely avoids this potential risk. 
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